Novel cell sources for bone regeneration

Chenshuang Li1 | Zane Mills2 | Zhong Zheng3,4

1 Department of Orthodontics, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
2 College of Dentistry, University of Oklahoma, Oklahoma City, Oklahoma, USA
3 Division of Growth and Development, School of Dentistry, University of California, Los Angeles, California, USA
4 Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, California, USA

Correspondence
Zhong Zheng, 675 Charles E Young Drive, South, MRL 2641, Los Angeles, CA 90095, USA.
Email: zzheng@dentistry.ucla.edu; leozz95@ad.ucla.edu

Abstract
A plethora of both acute and chronic conditions, including traumatic, degenerative, malignant, or congenital disorders, commonly induce bone disorders often associated with severe persisting pain and limited mobility. Over 1 million surgical procedures involving bone excision, bone grafting, and fracture repair are performed each year in the U.S. alone, resulting in immense levels of public health challenges and corresponding financial burdens. Unfortunately, the innate self-healing capacity of bone is often inadequate for larger defects over a critical size. Moreover, as direct transplantation of committed osteoblasts is hindered by deficient cell availability, limited cell spreading, and poor survivability, an urgent need for novel cell sources for bone regeneration is concurrent. Thanks to the development in stem cell biology and cell reprogramming technology, many multipotent and pluripotent cells that manifest promising osteogenic potential are considered the regenerative remedy for bone defects. Considering these cells’ investigation is still in its relative infancy, each of them offers their own particular challenges that must be conquered before the large-scale clinical application.

KEYWORDS
bone regeneration, multipotent stem cells, pluripotent stem cells

1 | INTRODUCTION

The typical human skeleton is composed of 206 bones; however, individuals may have varying numbers of bones present, including various small unnamed bones that generally form in high-friction areas. As the hardest and most rigid structures (aside from the teeth) in the body, bone provides mechanical support, mobility, and load-bearing capacity. In addition, bones play a critical role in the production of blood cells, the storage of minerals, and the regulation of the endocrine system.

Bone injuries comprise 25-30% of all musculoskeletal pathologies.1 Fortunately, bone is one of the few tissues with a robust innate self-healing repair mechanism of spontaneous resorption and reformation, allowing small bone injuries to heal in most cases.2 However, bone regeneration capacity is not sufficient in regard to reestablishing the skeletal system's integrity and functionality when the damage reaches a critical size, such as those resulting from severe injuries, maxillofacial surgeries of cleft palates, or salvage excision of tumors. A variety of musculoskeletal diseases and congenital conditions also significantly impair bone development and regeneration. In particular, osteoporosis and osteoarthritis are two prevalent diseases within the geriatric population that present major challenges for orthopedic reconstruction. Prevalence of these...
Various efforts have been made to improve bone regeneration for decades, including restricted or modified activity, immobilization of injured structure, acupuncture, physical therapy, administration of anti-inflammatory medication, application of corticosteroids, and revision surgeries. However, these therapies are palliative for bone defect management, as they do not directly stimulate the proliferation, differentiation, and maturation of osteogenic progenitor cells to reestablish the tissue; they merely alleviate the symptoms therein. Due to the advent of tissue engineering and regenerative medicine, new strategies to restore homeostasis in bone deficiency, such as bone graft usage, have been recently proposed. To date, the autogenous bone graft is still considered the gold standard for reconstructing large skeletal defects, as it not only provides a construction composed of a natural osteoconductive scaffold accompanied by supportive growth factors but also supplies immunotolerated osteogenic-committed cells.

Although this may be true, the limited resources for autogenous bone grafts and the harvesting procedure’s morbidity have fueled the search for alternative bone regeneration approach(s).

In order to be comparable to autogenous bone graft as the ideal blueprint for efficacious bone regeneration, any candidate therapies should provide one or more of the following: (1) a supportive osteoconductive or osteoinductive scaffold, (2) a suitable microenvironment to stimulate cellular osteogenesis differentiation and maturation, and (3) immune-tolerant osteogenic-committed cells or progenitor cells harboring the osteogenic potential in vivo.

In regard to the scaffold, functional material design has accelerated the application of biodegradable biomaterials in bone tissue engineering. Several diverse natural proteins (such as collagen, fibrin, and silk), polysaccharides (such as hyaluronic acid and chitosan), bioceramics, demineralized bone matrix, synthesized polymers (such as saturated aliphatic polyesters as presented by poly(D,L-lactic acid-co-glycolic acid), poly[(amino acid ester) phosphazenes], and their composites (such as collagen-hydroxyapatite-tricalcium phosphate complex and polyhydroxyalkanoate/ceramic complex) have been used to construct bone graft substitutes. Meanwhile, bone graft infection is one of the most serious complications in orthopedic surgery, as they are extremely difficult to treat and typically lead to significantly worse outcomes. Thus, antibiotics, such as gentamicin, and antisepsics, such as silver nanoparticles, are incorporated into the bone grafts to eliminate the contamination/infection and prohibit biofilm formation. These modified scaffolds provide a new avenue for winning the “race” between the infectious organisms that seek to contaminate, colonize, and ultimately infect the graft, and the body’s endogenous tissues or embedded exogenous osteogenic progenitors that seek to grow into the graft to attain a functional reunion. Meanwhile, numerous efforts have been devoted to scaffold optimization for accelerating the on growth cells proliferate and differentiate into the mature osseous tissue and deposit bone extracellular matrix (ECM).

Multiple growth factors have also been investigated to promote bone formation, among which bone morphogenetic protein 2 (BMP2; Infuse Bone Graft) has been approved for use in sinus augmentation and localized alveolar ridge augmentation. Although the osteogenic activity of BMP2 is well documented, its off-target effects such as postoperative inflammation, osteoclastogenesis, adipo genesis, and ectopic bone formation have also been recognized and raised concerns for clinical application of BMP2. Another intensively investigated group factor is BMP7 (also known as osteogenic protein-1 [OP-1]). Accumulating evidence demonstrates the efficacy of BMP7 on bone regeneration. Unfortunately, the application of BMP2 and BMP7 in the clinical settings faces an array of obstacles, including the high costs, lingering safety concerns (vertebral osteolysis, ectopic bone formation, radiculitis, or cervical soft tissue swelling), considerable failure rates, and controversies. Consequently, recombinant human BMP7 was withdrawn from the market, and restrictions were imposed in the clinical use of recombinant human BMP2. Aside from the BMP family members, other growth factors also step onto the arena of bone regeneration. For example, in 1999, Ting’s group first identified the osteogenic activity of another secretory protein, neural EGFL like 1 (NELL1), in active bone formation sites of human craniosynostosis patients. Since then, NELL1’s osteogenic potency has been verified in several small and large animal models consisting of rodents, sheep, and non-human primates without detecting the adverse effects seen in BMP2 administration. These studies suggest that NELL1 may be an alternative therapeutic option for local or systemic bone regeneration.

In addition to osteogenic growth factors, ultrasound and electrical stimulation are also used to promote bone regeneration. However, a recent systematic review of randomized controlled trials reveals that low-intensity pulsed ultrasound stimulation did not reduce time to return to work or the number of subsequent operations of patients with fractures, and its benefits on pain management, days to weight-bearing, and radiographic healing were also to be insignificant. Although the mechanism is not entirely understood, collagen’s piezoelectric property is able to generate a
2 | ADULT MESENCHYMAL STEM CELLS (MSCs)

2.1 | Adult MSCs were first isolated from bone marrow

In 1966, A. J. Friedenstein and colleagues detected the ectopic bone formation by a population of cells isolated from mature mouse bone marrow,\(^{101}\) which provided the first evidence endorsing Cohnheim’s hypothesis nonhematopoietic regenerative cells exist in the bone marrow.\(^{102}\) Under the appropriate in vitro culture condition, these colony forming unit-fibroblasts (CFU-F) can differentiate toward a wide range of cell types, including osteoblasts, chondrocytes, myocytes, and adipocytes. This being the case, these cells were retumed and are now commonly known as bone marrow-derived stromal cells (BMSCs). On account of their relationship with mesenchymal tissue development and regeneration, BMSCs are recognized as the prototype of MSCs.\(^{103}\) Since BMSCs enhanced bone healing in numerous small and large animal models,\(^{104,109}\) human BMSCs are considered the current gold-standard cell source for bone regeneration. For example, applying BMSCs to stimulate posterolateral spinal fusion was transferred from the preclinical investigation into the clinical assessment in 2008.\(^{110}\) However, the invasive and painful harvesting procedure presents a significant obstacle for BMSCs’ application. Also, the percentage of BMSCs among bone marrow nucleated cells obtained from bone marrow aspiration is typically 0.001-0.01%.\(^{111,112}\) Therefore, large quantities of bone marrow must be procured as starting material to obtain a substantial amount of BMSCs, causing additional donor site morbidity, and thus, remains extremely challenging for BMSCs’ clinical translation. Meanwhile, purification and expansion of BMSCs via passaging are generally necessary to eliminate other cell types.\(^{113}\) Unfortunately, BMSCs purified by the conventional plastic adherence method and assessed by the fibroblastic morphological criteria are heterogeneous populations containing a diversity of single stem cell-like and progenitor cells with different lineage commitment.\(^{114}\) As a result, even in the seemingly pure preparation of BMSCs, only a subpopulation of BMSCs will be susceptible to osteogenesis.\(^{115}\) Further, BMSCs have a relatively low proliferative ability, while the growth factors used to help BMSC expansion can jeopardize their differentiation potential.\(^{116-118}\)

In 2006, Aslan et al isolated a population of CD105 (endoglin)-expressing cells from bone marrow aspirate.\(^{119}\) Since these CD105\(^+\) cells can be culture-expanded, express CD90 but not CD14, CD34, CD45, or CD31, and are able to differentiate into osteogenic, chondrogenic, and
A plethora of both acute and chronic conditions, including traumatic, degenerative, malignant, and congenital varieties, often play key roles in reducing the quality of life for many people. This is particularly true in the case of critical-size defects where the innate self-healing capacity of bone is inadequate for a reunion. To date, a diversity of novel multipotent/pluripotent cell sources is regarded as regenerative medicine, particularly for bone regeneration, in virtue of continued worldwide collaboration. Although their potential is irrefutable, each of the cell sources mentioned has its own drawbacks, which must be entirely understood and overcome before they are released for human clinical application.

Adipogenic lineages, they could be considered a subsection of BMSCs according to the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy (ISCT) criteria. Excitingly, freshly immunoisolated CD105+ cells can differentiate into chondrocytes and osteoblasts in vivo with the stimulation with BMP2. A follow-up randomized and prospective preliminary study demonstrates the efficacy of these noncultured, immunoisolated CD105+ cells on fracture reunion in a clinical setting. However, these CD105+ cells only represent 2.3 ± 0.45% of the mononuclear cells in bone marrow aspirate. Therefore, novel technologies that easily and safely isolate sufficient highly osteogenesis-potential BMSCs are still urgently demanded.
2.2 | Adult MSCs can also be isolated from other tissues

To overcome the aforementioned disadvantages of BMSCs, great efforts have been made to collect MSCs from other tissues. Until now, in addition to bone marrow, MSCs were isolated from a broad range of tissues, such as perichondrium, cartilage, tendon, muscle, skin, dental pulp, gut, liver, and salivary glands. However, isolating MSCs from these tissues also involves invasive and painful harvesting procedures and is limited by the insufficient supply for cell harvesting.

2.2.1 | Oral-derived MSCs

One typical example is the dental pulp. Although studies on a laboratory-scale demonstrated the benefits of dental-pulp-derived MSCs (DMSCs) in the regeneration of craniofacial bone defects, the small yield of DMSCs from a single tooth leads to the long-term cultivation of DMSCs, accompanied with the escalated costs and risks to acquire sufficient DMSCs for clinical implementation. As a result, the regulatory bar for DMSCs seems extremely high. In addition to DMSCs, the oral cavity hosts several other stem cell populations capable of bone regeneration (as reviewed in Ref. 92), while similar cell availability limitation and regulatory concerns faced by DMSCs also hindered these cells’ clinical applications.

2.2.2 | Adipose-derived stem cells (ADSCs)

On the other hand, adipose tissue may provide an alternative avenue for MSCs isolation. The human adipose tissue is relatively abundant and can generally be obtained through a liposuction procedure. More importantly, adipose tissue yields a higher amount of MSCs than bone marrow: ADSCs can be harvested at the ratio of 5000 CFU-F per gram of adipose tissue; in other words, approximately 2% of nucleated cells in processed lipoaspirate are ADSCs. In comparison with BMSCs, ADSCs also have a great proliferation capability and are generally considered stable throughout long-term in vitro expansion, exhibiting their potential to be a practical regenerative medicine. Unfortunately, although it has become the second most common cosmetic surgical procedures, lipoaspiration/liposuction is still an invasive and painful surgery performed with anesthesia. Consequently, reports of severely secondary complications of lipoaspiration, such as blood clots, negative reactions to anesthesia, pulmonary complications, infections, and venous thromboembolism, have been significantly increased. Moreover, deaths secondary to lipoaspiration procedures are as high as one death in 5000 surgeries. Thus, lipoaspiration alone may not be safe for patients with heart problems or blood clotting disorders, women who are pregnant, or patients with a body mass greater than 35 kg/m² and thus is associated with a very high risk of secondary complications.

More importantly, combined procedures of lipoaspiration for ADSC harvesting and implantation for bone regeneration, particularly with obese or geriatric individuals, will significantly increase the complication rates and often lead to critical safety concerns.

2.3 | Definition of MSCs is still an open question under investigation

ADSCs are present in a stromal vascular fraction (SVF) that constitutes less than 10% of adipose tissue. SVF is a heterogeneous cell population, including preadipocytes, fibroblasts, vascular smooth muscle cells, endothelial cells, resident monocytes/macrophages, lymphocytes, and putative ADSCs. Because the presence of mixed stromal and endothelial cells in SVF may dilute and interact with the ADSCs, the benefit of SVF or unpurified ADSCs on bone regeneration is minimal. Consequently, a method to purify ADSCs from the SVF is vital, which turns out to post a question in regard to the characterization of MSCs.

Interestingly, MSCs, including BMSCs, DMSCs, ADSCs, and muscle-derived stem cells, are identified in cultures of its dissociated original tissues instead of their native character, frequency, and anatomic location. In 2006, the Mesenchymal and Tissue Stem Cell Committee of the ISCT established a four-point minimal criterium to define MSCs:

1. Are plastic-adherent when kept in standard culture conditions?
2. Are phenotypically positive for CD73, CD90, and CD105?
3. Lack of expression of CD45, CD34, CD14 or CD11b, CD19 or CD79α, and human leukocyte antigen-antigen D related (HLA-DR).
4. Hold the so-called “tri-lineage” differentiation potential towards osteoblasts, adipocytes, and chondroblasts in vitro.

It is worth noticing that CD44, a previously identified essential MSC-expression cell surface antigen, is not admitted to the ISCT standard. These criteria may be suitable for purifying ADSCs from SVF on account of the
more homogenous CD9+/CD44+/CD73+/CD90+ phenotype presented in the SVF after cultivation. Nonetheless, accumulating evidence suggests that these criteria may not be completely applicable for identifying ADSCs in vivo or isolating ADSCs from the bulk adipose tissue directly without additional in vitro cultivation steps. For instance, it is known that fibroblasts and stromal cells share the CD73+/CD105+/CD90+/CD44+ phenotype, and this quadruple-positive panel is only sufficient to discriminate these cells from hematopoietic counterparts.

The expression of CD34 is another important issue for characterizing MSCs in vivo. Traditionally, CD34 was considered a unique endothelial and hematopoietic marker, which should not be expressed by MSCs. Consequently, CD34 expression was used to identify and isolate hematopoietic stem cells (HSCs), and it was a common misconception that CD34+ cells represented the hematopoietic contamination in nonhematopoietic samples. Nevertheless, when Simmons and Torok-Storb originally generated the monoclonal antibody Stro-1, which has been extensively used as a selection tool of MSCs, CD34+ bone marrow cells were employed as the immunogen. Surprisingly enough, CD34+ cells constitute the majority of SVF cells (60-80%), and ADSCs harvested from liposapirate before in vitro cultivation exhibited some degree of CD34 expression, suggesting that CD34 may not be a real negative marker of MSCs in vivo. Meanwhile, CD34 expression is also present in various stem/progenitor cells, including muscle satellite cells, hair follicle stem cells, and keratinocyte stem cells. Further studies show that the standard passaging of ADSCs gradually declines the expression of CD34+, accompanied by the downregulation of other MSC-associated markers such as CD106, CD146, and CD271. The similar disappearance of CD34 expression was duplicated in muscle satellite cells when the cells were propagated and differentiated into adipogenic cells. Additionally, upon activation, the quiescent CD34+ keratocytes lost the CD34 expression and acquired a fibroblastic phenotype. Further, the high expression level of Stro-1 antigens in ADSCs is also diminished in response to passaging or induced differentiation. When considered together, these phenotypical shifts represent a response of multipotent cells to the environmental changes that induce an activation/differentiation from their in vivo quiescent state and indicate that CD34 could be treated as a common marker of quiescent multipotent stem/progenitor population, including ADSCs in vivo.

2.4 Adult MSCs are tightly related to pericytes and adventitial cells

Through their empirical work, Tintut et al demonstrated the multilineage differentiation potency of a subpopulation of vascular cells. Together with the distribution of Stro-1 antigens in adipose tissue predominantly located in the endothelium of arterioles, capillaries, and some veins, this report inspired an enthusiastic investigation to reveal the relationship between MSCs and perivascular cells. In mice, ADSCs have been shown to reside in the adipose vasculature with the expression of CD34 and stem cell antigen-1 (Sca-1; a marker for tissue-resident stem/progenitor cells) as well as three mura cell markers: α-smooth muscle actin (α-SMA), β-type platelet-derived growth factor receptor (PDGFRβ), and neural/glial antigen 2 (NG2). In 2008, Péault’s group demonstrated that pericytes derived from multiple human organs (including white adipose tissue, skeletal muscle, pancreas, placenta, heart, skin, lung, brain, eye, gut, bone marrow, and umbilical cord) display a CD34−/CD45−/HLADR−/CD44+/CD73+/CD90+/CD105− phenotype after in vitro cultivation. Moreover, when cultured in suitable conditions, pericytes exhibit the capability for colonial formation as well as osteogenic, chondrogenic, and adipogenic differentiation, which qualified them as MSCs based on the ISCT standard. This astonishing equivalency of pericytes with MSCs soon after drew the scientific community’s attention and led to the hypothesis that “all” MSCs are derived from pericytes.

The comparison between ADSCs and pericytes further emphasizes this theory. Interestingly, like ADSCs, intact pericytes in their native origin are positive for α-SMA, PDGFRβ, and NG2 expression, which is not diminished during in vitro expending. However, unlike mouse ADSCs that are CD34+ in vivo and early-passage in vitro, lack of CD34 expression in pericytes led to confusion regarding their natural affiliation.

In addition to the pericytes that closely associate with microvessel endothelial cells surrounding capillaries and microvessels, multipotent progenitor cells with MSC characteristics have also been isolated from the bovine artery wall and the tunica adventitia of the human pulmonary artery, which suggests the existence of nonpericyte perivascular cells as alternative originators of MSCs. After exclusion of myogenic (CD56) and hematopoietic (CD45) populations, two distinct populations derived from human white adipose tissue without the expression of endothelium-specific antigen CD31 could give rise to MSCs: CD146+/CD34− pericytes and a second CD146−/CD34+ population, because the clones developed from the CD146−/CD34+ cells displayed the MSC
Risk of rejection

Application of adult MSCs in tissue regeneration faces multiple obstacles

2.6

2.6.1 Risk of rejection

Similarly to the way in which autologous cell source is the best choice for clinical application, allogeneic MSCs must be considered in some scenarios such as the geriatric population, who are the primary targets for stem cell therapy since the therapeutic effectiveness of MSCs is dependent upon the age of the donor.242–245 MSCs were previously considered immunoprivileged246 because undifferentiated MSCs express low to intermediate levels of HLA class I and negligible to low HLA class II.120,247 However, MSCs exposed to interferon (IFN)-γ or differentiated into mature cell types can significantly express more HLA class I and HLA class II.248,249 Besides, long-term in vitro culture was reported to impair the immunosuppressive activity of MSCs.250 Moreover, animal model studies displayed a trend of the early death of allogeneic MSCs251–253 confirming in the human autopsy of patients who received allogeneic MSCs within a year.254 Furthermore, rejection and chronic immune responses of allogeneic MSCs have also been reported in animal studies and human clinical trials.255–257 Therefore, the current view of MSCs is “immunoevasive” instead of “immune-privileged.”258,259 Accurately measuring immune responses following MSCs treatment in a timely manner is necessary to assess the safety of allogeneic MSCs application. Also, developing novel technologies to prolong the “escaping” status of allogeneic

hallmark molecules CD44, CD73, CD90, and CD105, and can undergo osteogenic, adipogenic, and chondrogenic differentiation.222 Besides, flow cytometry analysis similarly confirmed that these CD146−/CD34+ adventitial cells homogeneously express the typical MSC-associated markers CD44, CD73, CD90, and CD105 in their native origin.222 Compared with pericytes, adventitial cells surround the largest vessels and are not closely associated with endothelial cells.222,223 Because adventitial cells hold the capability to differentiate into pericyte-like cells under inductive conditions in vitro, they are proposed to be the precursors of pericytes.222,223 A study evaluated human lipoaspirate from 70 donors to reveal that pericytes and adventitial cells comprise an average of 17.1% and 22.5% of SVF, respectively, which, in turn, accounts for approximately 39.6% of total nonadipocyte lipoaspirate cells or 3.96% of total adiponeuclidean cells.178

Although distinguishing these two populations provides significant impacts for stem cell biology research, combining pericytes and adventitial cells together—collectively termed perivascular stem cells (PSCs)—may maximize the MSC source in a clinical setting, especially when autologous cells are used to avoid immunogenic rejection. To bypass the in vitro cultivation steps for the plastic-adherent cells, which generally takes weeks and increases the risk of spontaneous cellular transformation, Péault’s group established a simple sorting procedure to safely and effectively obtain PSCs from routine liposuction.224 In this procedure, adipose tissues obtained from liposuction or lipectomy are first digested with collagenase and centrifuged to remove adipocytes. Then, the CD31+/CD45−/CD34+/CD146− pericytes and CD31−/CD45−/CD34−/CD146− adventitial cells are collected from the yielded SVF by fluorescent-activated cell sorting (FACS).178 Thanks to the effects of a multidisciplinary research group led by Drs. Péault and Soo, the entire procedure has been optimized to be completed in a few hours, making the direct sorting-based PSC application feasible in a clinical setting. As expected, the purified PSCs enhanced bone formation in animal models and were superior to SVF in forming bones.178,225–227 Thus, purified PSCs seem to be an alternative MSC source to confer bone formation.

2.5 Adult MSCs may benefit tissue repair via bioactive soluble factor production and secretion

In the last few decades, there has been a debate regarding the way in which MSCs ameliorate tissue damages. One possibility is that MSCs directly differentiate or transdifferentiate into parenchymal cells.228 Yet, previous studies showed a surprisingly low (less than 1%) and transient engraftment of MSCs in newly formed tissue given the associated therapeutic efficacy.229,230 A recent study that tracked the fate of pericytes in vivo in injured skeletal muscle or brain suggested that pericytes did not transdifferentiate as progenitor cells in these two circumstances, further questioning the direct engraftment of MSCs in tissue regeneration in vivo.231 Currently, it is believed that the long-lasting therapeutic benefits of MSCs rely on their bioactive soluble factor production and secretion.232–234 Particularly, by secreting trophic factors (growth factors, cytokines, and specific proteins), MSCs present their regenerative potency in neurovascular and musculoskeletal therapies.235,236 MSCs also produce multiple inflammatory cytokines to modulate the interaction between osteoblast-lineage and monocyte-macrophage-osteoclast lineage; both of which are essential for bone remodeling.237 Viewing MSCs as “an injury drugstore,”176,232,238–240 Dr. Arnold I. Caplan, a pioneer of MSCs research,103 suggested renaming the MSCs as “the Medicinal Signaling Cells” to more accurately depict their function in nature.232,234,241
MSCs from the donor’s immune system may prolong their persistence in vivo and improve their clinical outcomes.

2.6.2 | Risk of tumor formation

Another prudence of MSCs’ usage is their association with tumorigenesis. In 2005, Rubio et al reported the malignant transformation of human ADSCs that had passaged more than 4 months in vitro. In the same year, Wang et al identified an outgrowth transformed subpopulation of cultured human BMSCs with a round, cuboidal to short spindle shape, distinguished from the typical MSCs. These cells later termed transformed mesenchymal cells (TMCs), also displayed contact-independent growth and anchorage-independent growth when released into the suspension—typical phenotypes seen in tumorigenic cells with metastatic potential. Rosland et al reported that the ratio of spontaneous malignant transformation of human BMSCs to be as high as 45.8%. TMCs were also obtained in cultured mouse and monkey BMSCs, while injection of mouse and monkey TMCs resulted in tumor formation in recipient animals. Follow-up studies argued that spontaneous transformation of MSCs might be false, and the so-called TMCs may arise from the cross-contamination with malignant cells that were residents in origin, such as fibrosarcoma and osteosarcoma. This claim, whether correct or incorrect, highly emphasizes the drawback of the MSC expansion procedure. Nevertheless, this explanation may not be sufficient for lowering the tumorigenic caution for in vivo MSC implementation, especially for bone regeneration, as bone provides one of the most congenital metastatic microenvironment for tumor progression. Recent studies have shown that purified human MSCs developed chromosomal aberrations during cultivation and underwent spontaneous tumorigenic transformation, which cannot be explained by the cross-contamination theory. Recently, a significant amount of efforts have been devoted to optimizing the cultivation of MSCs, which may eventually result in a practical strategy to control the spontaneous tumorigenic transformation of MSCs. Certainly, accumulating data have also clearly demonstrated the unbalanced signal transduction in MSCs directly lead to sarcoma formation in vivo. Besides, the immune suppression potential of MSCs may diminish T-cell proliferation, thus weakening the antineoplastic response. More importantly, various cytokine, chemokines, and growth factors secreted by MSCs have been shown to increase the proliferation, migration, and angiogenesis of tumor cells. Akimoto et al revealed that ADMCs promote the growth of cocultured glioblastoma multiforme (GBM) cells in vitro and support GBM development in vivo by at least two distinct mechanisms—enhancing angiogenesis and inhibiting apoptosis. Meanwhile, Ren et al reported that similar to tumor-derived MSCs, tumor necrosis factor alpha (TNFα)-pretreated BMSCs enhanced tumor progression by recruiting more macrophages into tumor. This discovery highlights the possibility that, with an inflammatory stimulation, normal MSCs can convert into a more tumor-promising phenotype usually found in the tumor microenvironment. These direct and/or indirect involvements of MSCs in tumorigenesis suggest that MSCs hold a high risk for bone reconstruction patients with a history of malignancies.

Taken together, as the current gold standard cell source for bone engineering therapies, adult MSCs from different tissue were intensively investigated (Table 1). The identity, function, safety, and efficacy of these cells are still debatable. Aiming to answer these questions and optimize the clinical application of adult MSCs, a large-scale, expensive, and time-consuming investigation is inevitable, which will require a global collaboration of academia and pharmaceutical companies. In addition, the regulation of MSC-based therapies must be fully and accurately implemented, and most importantly, the long-term follow-ups that define the associated risks must be carried out in the clinical trials.

3 | FETAL MSCs

In addition to adult MSCs mentioned above, less mature MSCs isolated from the umbilical cord have been considered for bone regeneration. These umbilical cord-derived MSCs (UCMSCs) have similar surface marker expression, high differentiation potential, and low immunogenicity compared with BMSCs. Likewise, UCMSCs and BMSCs share the mitogen-activated protein kinase (MAPK) signal pathway for osteogenic commitment and differentiation. UCMSCs are isolated from umbilical cords, a generally discarded tissue, without ethical concerns, potential pain, and medical or surgical risks such as bleeding and anesthetic administration. Moreover, in comparison with adult MSCs, UCMSCs share a high expansion capability with other fetal-derived stem cells but rarely transform into tumor-associated fibroblasts. These advantages support the potential of UCMSCs for bone regeneration.

The human umbilical cord consists of an outer amniotic membrane (amniotic epithelium) that envelops a mucoid connective tissue, which can be characterized as three regions lacking clearly visible structural boundaries: Wharton's jelly, and adventitia (a strong, elastic muscle-like tissue layer), along with three blood vessels (a vein and two arteries). Among them, Wharton's
jelly contains the most abundant source of UCMSCs. A population of plastic-adherence, spindle-shaped cells that express CD44, CD73, CD90, and CD105, but not the hematopoietic markers CD14, CD34, or CD35, can also be isolated from the amniotic membrane, although the amniotic membrane was previously considered as solely epithelium and not a source of MSCs. These amniotic membrane-derived cells also have the tri-lineage differentiation potential and can be recognized by Stro-1. Thus, according to ISCT, they are qualified as MSCs and termed as amniotic membrane-derived MSCs (AMMSCs). A recent study showed that the proliferation and self-renewal capacity of AMMSCs are significantly lower than Wharton’s jelly-derived UCMSCs, indicating the disadvantages of AMMSCs to fulfill the clinical scale requirement in comparison with UCMSCs. Although recent comparison studies suggest that Wharton’s jelly-derived UCMSCs offer the best clinical utility (mainly due to the high isolation percentage and less nonstem cell contaminants to avoid excessive in vitro purification and expansion), the time-consuming and labor-intensive dissection of the cord into discrete regions may not be necessary to obtain a valuable population of cells for clinical application, particularly when FACS-based purification is employed.

Kargozer et al revealed that implantation of human UCMSCs with three-dimensional bioactive glass/gelatin scaffold in critical-sized calvarial defects resulted in a similar degree of bone formation compared to those implanted with unpurified human ADSCs, which is statistically lower than that of the human BMSC-implanted group. Interestingly, neovascularization was significantly increased in the human UCMSC group, leading to better healing than using the unpurified human ADSCs. In another study using RGD (Arg-Gly-Asp)-peptide-coated macroporous tetracalcium phosphate and dicalcium phosphate anhydrous as a scaffold, human BMSCs and UCMSCs resulted in similar levels of bone formation and vascularization in critical-sized calvarial defects. In addition to the influences of the different scaffold materials, another explanation of these paradoxical results could be the known fact that the yield and the differentiation potential of USMSCs highly depend on the method of cell isolation. Therefore, a standard isolation/purification methodology should be established and validated before the clinical application of UCMSCs.

Although UCMSMs hold the ability to modulate natural killer (NK) cells and promote regulatory T (Treg) cell expansion and thus present a lower rejection risk, immunogenic concern remains the main obstacle for their allogeneic usage. Meanwhile, the proper cryopreservation of the umbilical cord from childbirth for an extended time is an essential step for autologous usage, which is accompanied by nonnegligible financial and resource inputs.

Umbilical cord blood (UCB) was also recognized as a source of MSCs, although UCB has been considered a reliable source of HSCs for a long time. These UCB-derived MSCs (UCBMSCs) were also explored as an alternative cell source for bone tissue engineering and regeneration. Contrary to ADSCs that support GBM development, UCBMSCs inhibit GBM growth while simultaneously inducing apoptosis, suggesting that UCBMSCs are much safer than adult MSCs for clinical usage. However, UCBMSCs shared a similar immunogenic concern for allogeneic usage and costly storage difficulty for autologous application with UCMSMs. In addition, the yield of MSCs from UCB is extremely low, and the isolation of UCBMSCs is not guaranteed as UCMSMs, while UCMSMs also exhibit a great advantage in terms of proliferation. Amniotic fluid is another potential MSCs source; however, due to the invasive procedure, limited availability, and ethical concern, the yielded amniotic fluid MSCs (AFMSCs) will not be further discussed in this chapter, as there are no superior clinical benefits to use AFMSCs than to use aforementioned fetal MSCs based on the current understanding.
Generally, using fetal MSCs for tissue regeneration seems to be associated with higher technological and regulatory standards, as well as a significant financial burden. Making the fetal MSC-based therapies to be standard care available for everyone is tremendously challenging in reality, although it holds remarkable scientific interest and may be practical for some specific circumstances.

4 | EMBRYONIC STEM CELLS (ESCs)

In 1998, Thomson et al first derived the human ESCs from blastocysts. Briefly, the inner cell mass from the blastocyst stage of embryos is separated from the trophectoderm and plated onto mouse embryonic fibroblast feeder cells to form human ESC colonies. These human ESCs have normal karyotypes, exhibit high levels of telomerase activity, and display prolonged undifferentiated proliferation. They also express cell surface markers that characterize primate ESCs, present the ability to generate embryoid body (EB) in vitro, maintain the developmental potential to form trophoblast and derivatives of all three embryonic germ layers, and produce teratomas after injection into severe combined immunodeficient (SCID)-beige mice.

Since their discovery, human ESCs have been broadly used for drug discovery and development. As holding the pluripotent differentiation potential to any tissues, human ESCs have also been investigated as regenerative medicine, including the osteogenic aspect. Human ESC-based therapies develop very quickly, ie, from Thomson’s discovery of human ESCs to their clinical trial for spinal cord injury repair in 2009 (ClinicalTrials.gov Identifier: NCT01217008), it took merely 12 years.

Nevertheless, three inevitable impediments must be surmounted prior to the broad application of ESCs in humans. First, vigorous debates over ESC research and application ethics are continuing, as the human embryos have to be destroyed during the isolation of ESCs. To those who believe that “human life begins at conception” and an embryo is a person with the same moral status as an adult or a live-born child, taking a blastocyst and removing the inner cell mass to derive an ESC is equivalent to murder. On the contrary, many others believe that an embryo becomes a person in a moral sense at a later stage of development than fertilization. Taking this into account, the International Society for Stem Cell Research (ISSCR) issued a regulatory guideline that mandates the research on human embryos should be limited to the first two weeks after fertilization. Although this “14-day rule” reflects the laws of at least 12 countries, different administrations may hold varying positions in regard to the creation of new human ESCs, as seen in the Bush administration versus the Obama administration.

Second, the immunogenicity of ESCs should be disclosed, as their clinical usage is clearly allogeneic. To date, reports about the immunological properties of ESCs are still controversial, consisting of those that claim ESCs are uniquely immunoprivileged, those reveal that ESCs hold negligible immunogenicity, and those suggest ESCs can trigger an immune response.

Last but not least, the genomic instability and tumorigenic nature of ESCs raise a credible concern for their implantation in human bodies. Therefore, although the investigation of ESCs may pave the path for the investigation of reprogrammed pluripotent or multipotent cells, as discussed below, the clinical usage of ESCs seems impractical in the present stage.

5 | INDUCED PLURIPOTENT STEM CELLS (iPSCs)

5.1 | Generation iPSCs from diverse somatic cell origins in vitro starts a new era of cellular biology and regeneration medicine

Since circa 2006, somatic cells are now able to be reprogrammed into an ESC-like state with pluripotency utilizing viral-mediated genomic integration of a panel of transcriptional factors essential for embryonic development. The potential to use a patient’s own cells to create iPSCs provides a promising new venue for personalized cell therapies by overcoming the ethical paradox and potential immunogenicity of ESCs and fetal MSCs mentioned above. In addition, iPSCs can be directly derived from easily accessible and expandable dermal fibroblasts and blood cells, which places iPSCs above adult MSCs by avoiding the invasive harvest pressures to generate sufficient cell source. In acknowledgement of this breakthrough discovery, Dr. Shinya Yamanaka at Kyoto University was awarded the 2012 Nobel Prize in Physiology or Medicine.

Recently, there has been great enthusiasm for applying iPSCs for bone regeneration, with or without an MSC-intermediate stage. Initially, creating EBs from iPSCs before MSC generation was involved in gaining iPSC-derived MSCs (iPSC-MSCs), while soon after, an alternative strategy that obtained iPSC-MSCs from dissociated iPSC colonies without the EB formation step was employed. In comparison with adult MSCs, iPSC-MSCs not only have the advance in regard to proliferation but also present higher telomerase activity leading to less senescence, which is favorable for clinical application. Meanwhile, directly inducing osteogenic commitment of iPSCs without an MSC intermediate step...
was also reported by several independent groups around at the same time.\textsuperscript{180,386,388–405}

It has been demonstrated that the donor’s age has no effects on the differentiation potential of iPSCs,\textsuperscript{403} while some studies have revealed the influence of gender on the epigenetic stability of iPSCs.\textsuperscript{406} From scientific perspective, further investigations are warranted to elucidate the impotence of iPSCs’ epigenetic memory on their osteogenic commitment due to the current conflicting evidence and numerous variables in these studies\textsuperscript{369,403}, however, based on the clinical consideration of minimizing the risk of the cell harvesting procedure, dermal fibroblasts may be the top, if not the only, cell choice for iPSC generation.

Due to the fact that complex spatiotemporal signals and molecular interactions regulate the in vivo osteogenic commitment of pluripotent cells, a diversity of stimulation is applied to promote the direct osteogenic differentiation of iPSCs, including electronic stimulation,\textsuperscript{379} chemical inducers,\textsuperscript{180,363,365,367,374,375,379,380,382,389,400,402,403} small molecules\textsuperscript{362,380,404} growth factors in Refs.\textsuperscript{366, 374, 376, 380, 382, 389, 399, 403}, gene modification,\textsuperscript{361,365,370,377} as well as modified two-dimensional\textsuperscript{405} and three-dimensional microenvironment in Refs.\textsuperscript{364–366, 370–373, 375, 377, 378, 381–383, 387, 388, 391, 399–403}. Among which, osteogenic medium containing ascorbic acid, β-glycerophosphate, and dexamethasone formulation is most commonly used in vitro,\textsuperscript{363,364,367,374–376,379,382,389} while the three-dimensional porous scaffold or hydrogel is popular in vivo. Although some studies suggested that iPSC-MSCs may not completely differentiate into mature osteoblasts in vitro as evidenced by relatively lower or postponed expression of osteogenic markers, especially those indicating the late-stage osteogenic development,\textsuperscript{375,386,397,398} the performance of human iPSC-based therapies on bone regeneration was not worse, and maybe even better, than human BMSCs, ADMCs, and UCMSCs at the same circumstances in vivo.\textsuperscript{180,311,375}

5.2 Tumorigenesis is a significant drawback for iPSCs’ application in humans

“Above all, do no harm.”\textsuperscript{407} Tumor formation associated with cell transplantation must always be avoided in human use. The widely accepted procedure for iPSC generation, in which transcriptional factors essential for embryonic development (such as Yamanaka factors or Thomson factors) are introduced into the genome of target somatic cells, may induce unwanted gene activation and genomic alterations.\textsuperscript{408} As a result, iPSCs are likely to carry a higher tumorigenicity risk than ESCs.\textsuperscript{309–413} Teratoma formation was confirmed in about 20% of SCID mice that had received osteogenic-induced iPSC for bone defect regeneration.\textsuperscript{367} iPSCs also possess a potential risk for somatic tumor development, which is not present when using ESCs.\textsuperscript{414} iPSCs’ tumorigenic nature was considered an inevitable subsequence of retroviral or lentiviral transduction, resuling in genetic dysfunction, insertional mutagenesis, and tumor formation with genome integration. Thus, different integration-free techniques were explored for iPSC generation, including adenovirus,\textsuperscript{415,416} Sendai virus,\textsuperscript{417} expressing plasmid vector,\textsuperscript{418–420} episomal vector,\textsuperscript{421–423} single mini-circle vector,\textsuperscript{424} piggy-Bac transponson-based vector,\textsuperscript{425} RNA,\textsuperscript{426–429} and cell-penetrating protein.\textsuperscript{430,431} However, retroviral-derived and transgene-free human iPSCs exhibit similar tumorigenicity with no appreciable difference in teratoma formation capability or teratoma microvascular density.\textsuperscript{414,432} Meanwhile, great efforts are also being devoted to replacing Yamanaka factors (OCT4, SOX2, KLF4, and c-MYC) or Thomson factors (OCT4, SOX2, NANOG, and LIN28) that tightly associate with tumor progression by defined small molecules to achieve chemical induction of pluripotency (CIP).\textsuperscript{433–447} Nonetheless, current research indicates that bromodeoxyuridine (BrdU), a mutation inducer that can incorporate into the newly synthesized DNA by replacing thymidine during DNA replication, is required for CIP.\textsuperscript{447} In addition, iPSCs generated through CIP still possess a tumorigenic nature.\textsuperscript{433–447} Some reports suggested that using iPSC-MSCs may be safer than using iPSCs directly, as MSCs provide a relatively lower risk of tumorigenic deviation;\textsuperscript{392,448} however, the tumor-supporting potency of MSCs, as mentioned above, will also jeopardize the clinical application of iPSC-MSCs. In the interim, in order to prevent potential tumor formation from undifferentiated iPSCs, cell purification, such as flow cytometry- and magnetic bead-based sorting, is employed before transplantation and after differentiation to ensure that only well-differentiated cells will be transplanted in a generally adopted approach.\textsuperscript{449} Another strategy is to use iPSCs harboring a chemical-inducible suicide gene such that they will have to self-destruct when tumors are created.\textsuperscript{450,451} Moreover, resveratrol and irradiation were investigated to prohibit tumor formation from iPSCs and their derivatives during in vivo bone repair,\textsuperscript{362,367} which paves a new avenue to battle the “evil side” of iPSCs. Unfortunately, even only a small portion of undifferentiated iPSC contamination is still sufficient to induce tumor formation.\textsuperscript{410,450,451} Thus, purification and selective induction of cell death of undifferentiated iPSCs are inefficient and inadequate to eliminate the risk of teratoma and malignant tumors upon transplantation.\textsuperscript{449}

Taken together, while many challenges still exist before the bench-to-bedside translation of iPSC techniques, the high capacity of osteogenic differentiation of iPSCs grants
the cautious optimism of iPSCs’ promising potential to become a clinical reality in personalized bone tissue engineering and cell therapy.

6  |  FIBROMODULIN (FMOD)-REPROGRAMMED CELLS

6.1  |  Initial inspiration of fibromodulin reprogramming

Inspired by the pioneer exploration that transferred a somatic cell nucleus to an oocyte or fused a somatic cell with an ESC to gain pluripotency, Xenopus egg extracts, fish oocyte extracts, ESC extracts, and even carcinoma extracts are used to successfully obtain induced multipotent stem cells (iMSCs) from somatic cells. From a regulatory aspect, the undefined component of these extracts makes it almost impossible to use these iMSCs in humans. However, these studies strongly support the hypothesis that pluripotent cells’ surrounding microenvironment may play an important role in cell fate determination, including maintaining and/or inducing pluripotency.

As mentioned above, UCMSCs are predominantly harvested from Wharton’s jelly, a proteoglycan-rich connective tissue. Interestingly, like other fetal MSCs, UCMSCs seem to lie between the adult MSCs and ESCs on the development map as they present specific markers of ESCs in addition to those of adult MSCs. These observations provoke a question: can we reprogram connective tissue somatic cells to some degree of multipotent/pluripotent by reestablishing a proteoglycan-rich microenvironment?

Bi et al reported that FMOD, an ECM proteoglycan broadly distributed in connective tissues, is a critical component for maintaining endogenous stem cell niches by modulating the bioactivities of growth factors. As a 59-KD small leucine-rich proteoglycan (SLRP) member, FMOD contains a central region composed of leucine-rich repeats, with four keratan sulfate chains flanked by disulfide-bonded terminal domains. Holding high conservation among the mammalian species, FMOD core protein binds to an array of molecules including collagen, transforming growth factor β (TGFβ), and lysyl oxidase. Accumulating evidence provides that, in addition to its originally described roles in ECM structural support, FMOD also serves as a key regulator of intracellular signaling cascades that govern multiple biological processes, such as angiogenesis. During our long-time investigation into fetal scarless wound healing, we demonstrated that the single loss of FMOD is adequate to induce scar formation in early-gestation fetal animals, which normally heal without scarring. On the other hand, exogenous administration of FMOD is sufficient in restoring scarless fetal repair to late-gestation animals. This evidence not only highlights the essential role of FMOD plays in scarless fetal wound healing, but we also demonstrate that FMOD reduces scar formation in adult cutaneous wounds by eliciting a fetal-like phenotype of adult dermal fibroblasts. These studies suggest the potential of FMOD in cell rejuvenation and maybe even reprogramming.

6.2  |  Generation and characterization of FMOD-reprogrammed (FReP) cells

In 2012, we first reported a strategy to generate multipotent cells from human dermal fibroblasts by continuously stimulating with recombinant human FMOD under a serum-free condition. Through using this technology, dermal fibroblasts isolated from donors of different ages and genders have been successfully reprogrammed into a multipotent stage. The yield dome-shaped, clustered FReP cells can be easily separated from the surrounding spindle-shaped, monolayer FReP-basal cells with a Xenofree and enzyme-free reagent developed for passage of human ESCs and iPSCs. These FReP cells express the ESC/iPSC markers, such as NANOG, SOX2, SSEA4, TRA-1-60, and TRA-1-81, while their OCT4 expression is lower than that of iPSCs generated from the traditional viral-mediated method. The activation of these essential transcriptional factors for cell reprogramming, accompanied by a specific, biphasic Smad3 phosphorylation, was also validated by multiple methods. Similar to ESCs and iPSCs, FReP cells can form EBs in suspension culture and are capable of differentiating into neuron (ectoderm derivative), pancreatic lineage (endoderm derivative), and multiple mesoderm derivatives, such as osteoblasts, cardiomyocytes, skeletal myocytes, and adipocytes in vitro.

6.3  |  FReP cells exhibit superior potential for bone regeneration than iPSCs

Not only did FReP cell exhibit a similar capability of triploblastic differentiation in vitro as ESCs and iPSCs, the in vivo myogenesis and osteogenesis of FReP cells were also documented in SCID mouse models. Notably, in the broadly accepted critical-sized calvarial defect model, radiograph analysis revealed significantly more bone formation of the FReP cell implanted group than that of the empty scaffold, parent fibroblasts, and even iPSCs-implanted groups at eight weeks posttransplantation (Figure 2A). This observation was further supported by the
FIGURE 2 Radiographic analysis of bone regeneration in critical-sized SCID mouse calvarial defects at week eight postimplantation. Three days prior to implantation, \(5 \times 10^5\) tested cells were seeded on porous poly(D,L-lactic acid-co-glycolic acid)/hydroxyapatite scaffold and culture in an osteogenic medium containing ascorbic acid, \(\beta\)-glycerophosphate, and dexamethasone for in vitro induction. (A) MicroCT images of bone regeneration in critical-sized calvarial defects implanted with cell-free scaffold \((N=5)\), scaffold + parental BJ fibroblasts \((N=9)\), scaffold + BJ fibroblast-derived iPSC through conventional retrovirus-mediated method \(\text{BJ-iPSCs}; N=5\), and scaffold + BJ-FReP cells \((N=11)\). Images were documented at a resolution of 20.0 \(\mu\)m. Quantification of bone volume density \((B)\) and bone mineral density \((C)\) revealed that implantation of FReP cells resulted in significantly more new bone formation than other groups. *, statistical significance revealed by Mann-Whitney analysis; green stars indicate the difference from the cell-free scaffold group; red stars indicate the difference in comparison with the group of scaffold + FReP cells. Modified from Li et al482 with permission from Elsevier.

6.4 FReP cells carry significantly less tumorigenic risk than iPSCs

Like iPSCs, FReP cell generation is unfettered by the ethical and logistical constraints that overshadow the generation of ESCs. Another advantage of FReP cells is that they are generated from a protein-based technology without genome integration or oncogene activation. Importantly, unlike iPSCs that form teratomas as a consequence of the uncontrolled cellular proliferation,414 FReP cells have low proliferative capabilities under undifferentiated circumstances, which can be disrupted by osteogenic or myogenic stimulation.483 Under an intramuscular microenvironment, iPSCs implantation led to 25\% tumor formation, while no teratoma or other kinds of tumors were generated from FReP cells in SCID mice.484 Likewise, when FReP cells were intratesticularly implanted in Fox Chase SCID-Beige mouse with Matrigel\textsuperscript{\copyright} carrier, no teratoma was observed in a 4-month experimental period, while 100\% of the animals with iPSC implantation developed teratoma with progressive growth.484 Because teratoma formation of FReP cells was not found in the kidney capsule of Fox Chase SCID-Beige mouse either,481 FReP cells are considered to be a safer cell source for regenerative medicine than iPSCs. Albeit, as FReP cells' investigation is still in its infancy, an abundance of in-depth investigations must be conducted before translating FReP cells to a clinical setting, including but not limited to the optimization of productivity and the long-time safety and efficacy assessment.

6.5 FReP cells and multilineage differentiating stress enduring (MUSE) cells present a group of multipotent cell sources for regenerative medicine

Interestingly, FReP cells bear several critical characteristics of MUSE cells,481,483,485 (a) express pluripotent markers, albeit at lower levels than ESCs and iPSCs, (b) hold...
FIGURE 3 Engraftment, persistence, and osteogenesis of FReP cells in critical-sized SCID mouse calvarial defects at week eight postimplantation. Hematoxylin and eosin (H&E) and Masson’s trichrome staining confirmed that only minimal new bone regeneration occurs in the group implanted with the cell-free scaffold (A), while implantation of BJ-fibroblasts resulted in bone formation underneath the calvarial defect with obvious “cyst-like bone voids” in the newly generated bone area (B). The newly formed bone tissue was predominantly observed at the...
the capability to differentiate into all three germline cells under specific inductions, (c) have low levels of proto-oncogenes, such as \textit{LIN28} and \textit{c-MYC}, (d) retain a stable karyotype, and most importantly, (e) do not form teratomas. Although FReP cells and MUSE cells are both excluded from being considered pluripotent due to the stringent mandatory criteria of teratoma formation when introduced to an in vivo environment, they may represent a different group of cells processing triploblastic differentiation capability that holds tremendous potential in regenerative medicine.

Nevertheless, FReP cell generation is distinct from MUSE cell collection. Activation and isolation of MUSE cells require severe cellular stress conditions, such as lengthy incubation and digestion, hypoxia, and low temperatures,\textsuperscript{485} which assist in killing off all of the other viable cells. FMOX reprogramming does not require hypoxia or low temperatures, and the resultant FReP cells and FReP-basal cells are both viable. FReP cells resemble quiescent stem cells in multiple ways,\textsuperscript{483} and as such, the mechanism by which FMOX assists in reprogramming demands a thorough exploration. Bearing in mind the multiple striking similarities shared by FReP and MUSE cells, the relationship between these two populations should also be further investigated. MUSE cells are considered a primary source of iPSCs in human fibroblasts in the elite model for iPSC generation.\textsuperscript{486,487} However, the mechanism governing the transition from nontumorigenic MUSE cells to tumorigenic iPSCs remains an enigma. Further exploration into the mechanism of MUSE cell generation, as well as FMOX reprogramming, may also benefit to clarify the molecular roadmap of somatic cell reprogramming in general.

7 | CONCLUSION

A diversity of novel multipotent/pluripotent cell sources is recruited as regenerative medicine outlets (Figure 1), particularly for bone regeneration in virtue of continued worldwide collaboration. Although their potential is irrefutable, and the opportunity to develop personalized cell therapy (in the cases of iPSCs and FReP cells) is extremely enticing, each of these cell sources has its own obstacles (Table 2) that must be understood entirely and overcome before they may be used on a large scale in a clinical setting. Despite the preliminary efficacy and safety assessment in a laboratory setting, further clinical data are necessary to determine their therapeutic benefits and safety, as well as to optimize their use as a part of the novel regenerative medicine strategy. Furthermore, ways in which we can promote seeding cells survive, growth, and differentiation into desired tissues via the implantation vehicle or scaffolds is also an open question for global collaboration, although previous studies may already point out some fundamental directions.\textsuperscript{31,52} We believe that in light of the currently existing evidence, a new era of cell-based bone regeneration is becoming a reality with the continued collaborative efforts of scientists, physicians, industry, and regulatory agencies.

ACKNOWLEDGMENTS

The authors would like to thank Drs. Kang Ting and Chia Soo from the University of California, Los Angeles, for their enthusiastic support.

CONFLICT OF INTERESTS

Dr. Zhong Zheng is an inventor on FMOX-related patents assigned to UCLA, and a founder and an office of Scarless Laboratories Inc., which sublicenses fibromodulin-related patents from the UC Regents. Dr. Zheng also holds equity in the company.

CONTRIBUTIONS

Dr. Chenshuang Li drafted the manuscript, Mr. Zane Milles conducted the literature collection and proofreading, and Dr. Zhong Zheng conceived the ideas of the manuscript and provided revisions to the scientific concept. All authors read and approved the final manuscript.

ETHICS APPROVAL STATEMENT

Ethical approval not applicable to this review article. They will have been obtained from the original authors of the cited references.

DATA AVAILABILITY STATEMENT

Data sharing not applicable to this article as no new datasets were generated for this review article.
### Summary of novel cell sources for bone regeneration discussed in this review

| Cell types | Pros | Cons |
|------------|------|------|
| **Adult MSCs** | 1. Intensively investigated 2. Possible benefit of tissue regeneration by secreting trophic factors 3. Immuno-evasive | 1. Invasive and painful harvesting procedure 2. May not directly differentiate or transdifferentiate into the desired tissues 3. Reported rejection and chronic immune response of allogeneic MSCs 4. Support or directly involved in tumor formation |
| **Fetal MSCs** | 1. Isolated from generally discarded tissues without ethical concerns, potential pain, and medical or surgical risks 2. Highly expansible 3. Low rejection risks 4. Rarely transform to tumor-associated phenotype 5. Induce apoptosis of tumor cells | 1. Lack of standard isolation and purification methodologies 2. Lack of regulatory standards 3. Associated with higher costs |
| **ESCs** | 1. Pluripotency 2. Fast development and intensively investigated | 1. Ethical dilemma 2. Data of immunogenicity is not fully revealed 3. Genomic instability 4. Tumorigenic nature |
| **iPSCs** | 1. Breakthrough discovery 2. Worldwide collaboration established 3. Could be derived from patients’ own cells, such as fibroblasts and blood cells 4. Minimal risk of invasive harvesting procedure and rejection | 1. Genomic instability 2. Signiant tumorigenic risk |
| **FReP cells** | 1. Could be derived from patients’ fibroblasts 2. Minimal risk of invasive harvesting procedure and rejection 3. Superior potential for bone regeneration compared to iPSCs 4. No genomic integration or oncogene activation 5. Significantly lower tumorigenic risk | 1. Investigation in its infancy |
| **MUSE cells** | 1. No genomic integration or oncogene activation 2. Significantly lower tumorigenic risk | 1. Investigation in its infancy 2. Invasive and painful harvesting procedure 3. Severe cellular stress conditions for purification |

---

**ORCID**
Zhong Zheng https://orcid.org/0000-0002-4905-3563

**REFERENCES**

1. United States Bone and Joint Initiative: The Burden of Musculoskeletal Diseases in the United States. In: Chapter 6: Musculoskeletal injuries, 2nd ed. Rosemont, IL: American Academy of Orthopaedic Surgeon; 2011:129-143.
2. Loi F, Cordova LA, Pajarinen J, Lin TH, Yao Z, Goodman SB. Inflammation, fracture and bone repair. Bone. 2016;86:119-130.
3. Melton LJ, Chrisehilles EA, Cooper C, Lane AW, Riggs BL. How many women have osteoporosis. *J Bone Miner Res*. 1992;7(9):1005-1010.
4. Melton LJ, Atkinson EJ, O’Connor MK, O’Fallon WM, Riggs BL. Bone density and fracture risk in men. *J Bone Miner Res*. 1998;13(12):1915-1923.
5. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmo. *Osteoporosis Int*. 2000;11(8):669-674.
6. What is osteoporosis? International Osteoporosis Foundation. https://www.iofbonehealth.org/what-is-osteoporosis/.
7. What is osteoporosis and what causes it? National Osteoporosis Foundation. https://www.nof.org/patients/what-is-osteoporosis/.
8. Goodman SB, Gibon E, Pajarinen J, et al. Novel biological strategies for treatment of wear particle-induced periprosthetic osteolysis of orthopaedic implants for joint replacement. *J R Soc Interface*. 2014;11(93):20130962.
9. Gomez-Barrena E, Rosset P, Lozano D, Stanovici J, Ernhaller C, Gerbhard F. Bone fracture healing: cell therapy in delayed unions and nonunions. *Bone*. 2015;70:93-101.
10. Ong JL, Guda T. *Translating Biomaterials for Bone Graft: Bench-Top to Clinical Applications*. Boca Raton, FL: CRC Press, Talyor & Francis Group; 2017:1-263.
11. Wang W, Yeung KWK. Bone grafts and biomaterials substitutes for bone defect repair: a review. Bioactive Mater. 2017;2(4):224-247.

12. Pirris SM, Nottmeier EW, Kimes S, O’Brien M, Rahmathulla G. A retrospective study of iliac crest bone grafting techniques with allograft reconstruction: do patients even know which iliac crest was harvested? Clinical article. J Neurosurg Spine. 2014;21(4):595-600.

13. Narotam PK, Jose S, Nathoo N, Taylor C, Vora Y. Collagen matrix (DuraGen) in dural repair: a new of modified technique. Spine. 2004;29(24):2861-2867; discussion 2868-2869.

14. Sumanasinghe RD, Bernacki SH, Loboa EG. Osteogenic differentiation of human mesenchymal stem cells in collagen matrices: effect of uniaxial cyclic tensile strain on bone morphogenetic protein (BMP-2) mRNA expression. Tissue Eng. 2006;12(12):3459-3465.

15. Sumanasinghe RD, Osborne JA, Loboa EG. Mesenchymal stem cell-seeded collagen matrices for bone repair: effects of cyclic tensile strain, cell density, and matrix conditions on matrix contraction in vitro. J Biomed Mater Res A. 2009;88(3):778-786.

16. Chan BP, Hui TY, Wong MY, Yip KH, Chan GC. Mesenchymal stem cell-encapsulated collagen microspheres for bone tissue engineering. Tissue Eng Part C Methods. 2010;16(2):225-235.

17. Jovanovic SA, Hunt DR, Bernard GW, Spiekermann H, Wozney JM, Wikesjo UM. Bone reconstruction following implantation of rhBMP-2 and guided bone regeneration in canine alveolar ridge defects. Clin Oral Implants Res. 2007;18(2):224-230.

18. Ahmed TA, Dare EV, Hincke M. Fibrin: a versatile scaffold for tissue engineering applications. Tissue Eng Part B Rev. 2008;14(2):199-215.

19. de la Puente P, Ludeña D. Cell culture in autologous fibrin scaffolds for applications in tissue engineering. Exp Cell Res. 2014;322(1):1-11.

20. Li C, Vepari C, Jin HJ, Kim HJ, Kaplan DL. Electrospun silk-BMP-2 scaffolds for bone tissue engineering. Biomaterials. 2006;27(16):3115-3124.

21. Kim HJ, Kim UI, Kim HS, et al. Bone tissue engineering with premineralized silk scaffolds. Bone. 2008;42(6):1226-1234.

22. Mieszawska AJ, Fourligas N, Georgakoudi I, et al. Osteoinductive silk-silica composite biomaterials for bone regeneration. Biomaterials. 2010;31(34):8902-8910.

23. Kim J, Kim IS, Cho TH, et al. Bone regeneration using hyaluronic acid-based hydrogel with bone morphogenetic protein-2 and human mesenchymal stem cells. Biomaterials. 2007;28(10):1830-1837.

24. Kim J, Kim IS, Hwang SJ, Kim HC, Park Y, Sun K. Bone regeneration using MMP sensitive-hyaluronic acid based hydrogels. 2009 35th Annual Northeast Bioengineering Conference. 2009:42.

25. Patterson J, Siew R, Herring SW, Lin ASP, Guldberg R, Stanton PS. Hyaluronic acid hydrogels with controlled degradation properties for oriented bone regeneration. Biomaterials. 2010;31(26):6772-6781.

26. Levenood SL, Zhang M. Chitosan-based scaffolds for bone tissue engineering. J Mater Chem B Mater Biol Med. 2014;2(21):3161-3184.

27. Cicco SR, Vona D, De Giglio E, et al. Chemically modified diatom biosilica for bone cell growth with combined drug-delivery and antioxidant properties. ChemPlusChem. 2015;80(7):1104-1112.

28. Venkatesan J, Vinodhini PA, Sudha PN, Kim SK. Chapter five - chitin and chitosan composites for bone tissue regeneration. Adv Food Nutr Res. 2014;73:59-81.

29. Deepthi S, Venkatesan J, Kim SK, Bungardner JD, Jayakumar R. An overview of chitin or chitosan/nano ceramic composite scaffolds for bone tissue engineering. Int J Biol Macromol. 2016;93:1338-1353.

30. Tamburaci S, Tihminioglu F. Diatomite reinforced chitosan composite membrane as potential scaffold for guided bone regeneration. Mater Sci Eng C. 2017;80:222-231.

31. Baiño F, Novajra G, Vitale-Brovarone C. Bioceramics and scaffolds: a winning combination for tissue engineering. Front Bioeng Biotechnol. 2015;3:202.

32. Kuttappan S, Mathew D, Nair MB. Biomimetic composite scaffolds containing bioceramics and collagen/gelatin for bone tissue engineering - a mini review. Int J Biol Macromol. 2016;93(Pt B):1390-1401.

33. Denes E, Barriere G, Poli E, Leveque G. Commentary: bioceramics and scaffolds: a winning combination for tissue engineering. Front Bioeng Biotechnol. 2017;5:15.

34. van der Stok J, Hartholt KA, Schoenmakers DAL, Arts JJC. The available evidence on demineralised bone matrix in trauma and orthopaedic surgery: a systematic review. Bone Joint Res. 2017;6(7):423-432.

35. Gentile P, Chiono V, Carmagnola I, Hatton PV. An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. Int J Mol Sci. 2014;15(3):3640-3659.

36. Zheng Z, Yin W, Zara JN, et al. The use of BMP-2 coupled - Nanosilver-PLGA composite grafts to induce bone repair in grossly infected segmental defects. Biomaterials. 2010;31(35):9293-9300.

37. Nair LS, Laurencin CT. Polymers as biomaterials for tissue engineering and controlled drug delivery. Adv Biochem Eng Biotechnol. 2006;102:47-90.

38. Nair LS, Lee DA, Bender JD, et al. Synthesis, characterization, and osteocompatibility evaluation of novel alanine-based polyphosphazenes. J Biomed Mater Res A. 2006;76(1):206-213.

39. Kretlow JD, Young S, Klouda L, Wong M, Mikos AG. Injectable biomaterials for regenerating complex craniofacial tissues. Adv Mater. 2009;21(32-33):3368-3393.

40. Goonoo N, Bhaw-Luximon A, Passanha P, Esteves SR, Jhurry D. Third generation poly(hydroxyacid) composite scaffolds for tissue engineering. J Biomed Mater Res B Appl Biomater. 2017;105(6):1667-1684.

41. Song R, Murphy M, Li C, Ting K, Soo C, Zheng Z. Current development of biodegradable polymeric materials for biomedical application. Drug Des Devel Ther. 2018;12:3117-3145.

42. Gomez J, Rodriguez M, Banos V, et al. Orthopedic implant infection: prognostic factors and influence of long-term antibiotic treatment on evolution. Prospective study, 1992–1999. Enferm Infec Microbiol Clin. 2003;21(5):232-236.

43. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med 2004;350(14):1422-1429.

44. Giavaresi G, Borsari V, Fini M, et al. Preliminary investigations on a new gentamicin and vancomycin-coated PMMA nail for the treatment of bone and intramedullary infections: an experimental study in the rabbit. J Orthop Res. 2008;26(6):785-792.

45. Shirai T, Tsuchiya H, Shimizu T, Ohtani K, Zen Y, Tomita K. Prevention of pin tract infection with titanium-copper alloys. J Biomed Mater Res B Appl Biomater. 2009;91(1):373-380.
46. Khosravi AD, Ahmadi F, Salmanzadeh S, Dashtbozorg A, Montazeri EA. Study of bacteria isolated from orthopedic implant infections and their antimicrobial susceptibility pattern. *Res J Microbiol*. 2009;4(4):158-163.

47. Campoccia D, Montanaro L, Arciola CR. The significance of infection related to orthopedic devices and issues of antibiotic resistance. *Biomaterials*. 2006;27(11):2331-2339.

48. Josefsson G, Kolmert L. Prophylaxis with systematic antibiotics versus gentamicin bone cement in total hip arthroplasty. A ten-year survey of 1,688 hips. *Clin Orthop Relat Res*. 1993(292):210-214.

49. Liu Y, Zheng Z, Zara JN, et al. The antimicrobial and osteoinductive properties of silver nanoparticle/poly (DL-lactic-co-glycolic acid)-coated stainless steel. *Biomaterials*. 2012;33(34):8745-8756.

50. Murphy M, Ting K, Zhang XL, Soo C, Zheng Z. Current development of silver nanoparticle preparation, investigation, and application in the field of medicine. *J Nanomater*. 2015;696918.

51. Marrelli M, Maletta C, Inchingolo F, Alfano M, Tatullo M. Three-point bending tests of zirconia core/veneer ceramics for dental restorations. *Int J Dent*. 2013;2013:831976.

52. Marrelli M, Puja A, Palmieri F, et al. Innovative approach for the in vitro research on biomedical scaffolds designed and customized with CAD-CAM technology. *Int J Immunopathol Pharmacol*. 2016;29(4):778-783.

53. Schultz DG. *FDA Public Health Notification: Life-Threatening Complications Associated with Recombinant Human Bone Morphogenetic Protein in Cervical Spine Fusion*. Health CDAR, Food and Drug Administration; 2008.

54. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. *Spine J*. 2011;11(6):471-491.

55. Balseiro S, Nottmeier EW. Vertebral osteolysis originating from subchondral cyst end plate defects in transforaminal lumbar interbody fusion using rhBMP-2. Report of two cases. *Spine J*. 2010;10(7):e6-e10.

56. Kaneko H, Arakawa T, Mano H, et al. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. *Bone*. 2000;27(4):479-486.

57. Sciadini MF, Johnson KD. Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. *J Orthop Res*. 2000;18(2):289-302.

58. Zara JN, Siu RK, Zhang X, et al. High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation *in vivo*. *Tissue Eng Part A*. 2011;17(9-10):1389-1399.

59. Dunn CA, Jin Q, Taba M Jr., Franceschi RT, Bruce Rutherford R, Giannobile WV. BMP gene delivery for alveolar bone engineering at dental implant defects. *Mol Ther*. 2005;11(2):294-299.

60. Lee YJ, Lee TJ, Cho HJ, Kim HK, Yoon TR, Shin H. Electrospun fibers immobilized with bone forming peptide-1 derived from BMP7 for guided bone regeneration. *Biomaterials*. 2013;34(21):5059-5069.

61. Zhang YF, Wu CT, Luo T, Li S, Cheng XR, Miron RJ. Synthesis and inflammatory response of a novel silk fibroin scaffold containing BMP7 adenovirus for bone regeneration. *Bone*. 2012;51(4):704-713.

62. Sun P, Wang JX, Zheng YN, Fan Y, Gu ZY. BMP2/7 heterodimer is a stronger inducer of bone regeneration in peri-implant bone defects model than BMP2 or BMP7 homodimer. *Dent Mater J*. 2012;31(2):239-248.

63. Williams JC, Maitra S, Anderson MJ, Christiansen BA, Reddi AH, Lee MA. BMP-7 and Bone regeneration: evaluation of dose-response in a rodent segmental defect model. *J Orthop Trauma*. 2015;29(9):e336-341.

64. Govender S, Csimma C, Genant HK, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. *J Bone Joint Surg Am*. 2002;84(12):2123-2134.

65. Shimer AL, Oner FC, Vaccaro AR. Spinal reconstruction and bone morphogenetic proteins: open questions. *Injury*. 2009;40(Suppl 3):S32-38.

66. Lissenberg-Thunnissen SN, de Gorster DJJ, Sier CFM, Schipper IB. Use and efficacy of bone morphogenetic proteins in fracture healing. *Int Orthop*. 2011;35(9):1271-1280.

67. Sreekumar V, Aspera-Werz RH, Tendulkar G, et al. BMP9 a possible alternative drug for the recently withdrawn BMP7? New perspectives for (re-)implementation by personalized medicine. *Arch Toxicol*. 2017;91(3):1353-1366.

68. Ting K, Vastardis H, Mulliken JB, et al. Human NELL-1 expressed in unilateral coronal synostosis. *J Bone Miner Res*. 1999;14(1):80-89.

69. Aghaloo T, Cowan CM, Chou YF, et al. Nell-1-induced bone regeneration in calvarial defects. *Am J Pathol*. 2006;169(3):903-915.

70. Li W, Zara JN, Siu RK, et al. Nell-1 enhances bone regeneration in a rat critical-sized femoral segmental defect model. *Plast Reconstr Surg*. 1995;96(6):1251-9. discussion 1260-1. 2011;127(2):580-587.

71. Siu RK, Lu SS, Li W, et al. Nell-1 protein promotes bone formation in a sheep spinal fusion model. *Tissue Eng Part A*. 2011;17(7-8):1123-1135.

72. James AW, Shen J, Zhang X, et al. NELL-1 in the treatment of osteoporotic bone loss. *Nat Commun*. 2015;6:7362.

73. James AW, Fan A, Chiang M, et al. A new function of Nell-1 protein in repressing adipogenic differentiation. *Biochem Bioph Res Commun*. 2011;411(1):126-131.

74. Xue J, Peng J, Yuan M, et al. NELL1 promotes high-quality bone regeneration in rat femoral distraction osteogenesis model. *Bone*. 2011;48(3):485-495.

75. Shen J, James AW, Zara JN, et al. BMP2-Induced inflammation can be suppressed by the osteoinductive growth factor NELL-1. *Tissue Eng Part A*. 2013;19(21-22):2390-2401.

76. Shen J, James AW, Zhang X, et al. Novel Wnt regulator NELL-like molecule-1 antagonizes adipogenesis and augments osteogenesis induced by bone morphogenetic protein 2. *Am J Pathol*. 2016;186(2):419-434.

77. Yang MH, Lim KT, Choung PH, Cho CS, Chung JH. Application of ultrasound stimulation in bone tissue engineering. *Int J Stem Cells*. 2010;3(2):74-79.

78. Jacobs A. Bone growth stimulation: what the evidence reveals. *Podiatry Today*. 2016;29(5):44-48.

79. Schandelmaier S, Kaushal A, Lytvyn L, et al. Low intensity pulsed ultrasound for bone healing: systematic review of randomized controlled trials. *BMJ*. 2017;356:j656.
80. Nair AK, Gautieri A, Chang S-W, Buehler MJ. Molecular mechanics of mineralized collagen fibrils in bone. Nat Commun. 2013;4:1724-1732.

81. Black J, Baranowski T, Brighton C. Electrochemical aspects of dc stimulation of osteogenesis. Bioelectrochem Bioenerg. 1984;12(3):323-327.

82. Bodamyali T, Kanczler J, Simon B, Blake D, Stevens C. Effect of faradic products on direct current-stimulated calvar- ial organ culture calcium levels. Biochem Biophys Res Commun. 1999;264(3):657-661.

83. Shirkhanzadeh M. Direct formation of nanophase hydroxyapatite on cathodically polarized electrodes. J Mater Sci Mater Med. 1998;9(2):67-72.

84. Ishaug SL, Crane GM, Miller MJ, Yasko AW, Yaszemski MG. I. Evaluation of quantitative histological areas promote osteogenesis. NPG Asia Mater. 2016;8(3):e243-250.

85. Wang Z, Clark CC, Brighton CT. Up-regulation of bone morphogenetic proteins in cultured murine bone cells with use of specific electric fields. J Bone Joint Surg Am. 2006;88(5):1053-1065.

86. Ning C, Yu P, Zhu Y, et al. Built-in microscale electrostatic fields induced by anatase—rutile-phase transition in selective areas promote osteogenesis. ACS Appl Mater Interfaces. 2018;10(18):15449-15460.

87. Zhang Y, Zheng Z, Yu M, et al. Using an Engineered galvanic redox system to generate positive surface potentials that promote osteogenic functions. J Mater Sci: Mater Med. 2018;29(29):3973-3982.

88. Sacchetti B, Funari A, Michienzi S, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 2007;131(2):324-336.

89. Chan CKF, Gulati GS, Sinha R, et al. Identification of the human skeletal stem cell. Cell. 2018;175(1):43-56 e21.

90. Ballini A, Cantore S, Scacco S, Coletti D, Tatullo M. Mesenchymal stem cells as promoters, enhancers, and playmakers of the translational regenerative medicine 2018. Stem Cells Int. 2018;2018:6927401.

91. Ballini A, Scacco S, Coletti D, Pluchino S, Tatullo M. Mesenchymal stem cells as promoters, enhancers, and playmakers of the translational regenerative medicine. Stem Cells Int. 2017;2017:3292810.

92. Spagnuolo G, Codispoti B, Marrelli M, Rengo C, Rengo S, Tatullo M. Commitment of oral-derived stem cells in dental and maxillofacial applications. Dent J (Basel). 2018;6(4).

93. Ambrosi TH, Longaker MT, Chan CKF. A revised perspective of skeletal stem cell biology. Front Cell Dev Biol. 2019;7: 189.

94. Ishaug SL, Crane GM, Miller MJ, Yasko AW, Yassemzski MJ, Mikos AG. Bone formation by three-dimensional stromal osteoblast culture in biodegradable polymer scaffolds. J Biomed Mater Res. 1997;36(1):17-28.

95. Yamanouchi K, Satomura K, Gotoh Y, et al. Bone formation by transplanted human osteoblasts cultured within collagen sponge with dexamethasone in vitro. J Bone Miner Res. 2001;16(5):857-867.

96. Park MS, Kim SS, Cho SW, Choi CY, Kim BS. Enhancement of the osteogenic efficacy of osteoblast transplantation by the sustained delivery of basic fibroblast growth factor. J Biomed Mater Res B. 2006;79B(2):353-359.

97. Becker AJ, Till JE, Mcculloch EA. Cytological demonstration of clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature. 1963;197(486):452-454.

98. Wang Y, Han ZB, Song YP, Han ZC. Safety of mesenchymal stem cells for clinical application. Stem Cells Int. 2012;2012:652034.

99. Asatryan G, Pham D, Hardy WIR, James AW, Peault B. Stem cell technology for bone regeneration: current status and potential applications. Stem Cells Cloning. 2015;8:39-48.

100. Walmsley GG, Ransoms RC, Zelkis ER, et al. Stem cells in bone regeneration. Stem Cell Rev Rep. 2016;12(5):524-529.

101. Friedenstein AJ, Piatetzky S, II, Pettrakova KV. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol. 1966;16(3):381-390.

102. Cohnheim J. Ueber entzundung und eiterung. Arch für Pathol Anatomie Physiol klinische Medizin. 1867;40:1-79.

103. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9(5):641-650.

104. Minamide A, Yoshida M, Kawakami M, et al. The use of cultured bone marrow cells in type I collagen gel and porous hydroxyapatite for posterolateral lumbar spine fusion. Spine. 2005;30(10):1134-1138.

105. Hutton DL, Grayson WL. Stem cell-based approaches to engineering vascularized bone. Curr Opin Chem Eng. 2014;3:75-82.

106. Zhao JJ, Yang CB, Su C, et al. Reconstruction of orbital defects by implantation of antigen-free bovine cancellous bone scaffold combined with bone marrow mesenchymal stem cells in rats. Graef Arch Clin Exp. 2013;251(5):1325-1333.

107. Fernandes MBC, Guimaraes JAM, Casado PL, et al. The effect of bone allografts combined with bone marrow stromal cells on the healing of segmental bone defects in a sheep model. BMC Vet Res. 2014;10:1-12.

108. Velez R, Hernandez-Fernandez A, Caminal M, et al. Treatment of femoral head osteonecrosis with advanced cell therapy in sheep. Arch Orthop Trauma Surg. 2012;132(11):1611-1618.

109. Shamsul BS, Tan KK, Chen HC, Aminuddin BS, Ruszymah BHI. Posterolateral spinal fusion with osteogenesis induced BMSC seeded TCP/HA in a sheep model. Tissue Cell. 2014;46(2):152-158.

110. Gan YK, Dai KR, Zhang P, Tang TT, Zhu ZN, Lu JX. The clinical use of enriched bone marrow stem cells combined with porous beta-tricalcium phosphate in posterior spinal fusion. Biomaterials. 2008;29(29):3973-3982.

111. Rickard DJ, Kassem M, Hefferan TE, Sarkar G, Spelsberg TC, Riggs BL. Isolation and characterization of osteoblast pre-cursor cells from human bone marrow. J Bone Miner Res. 1996;11(3):312-324.

112. Stenderup K, Justesen J, Eriksen EF, Rattan SIS, Kassem M. Number and proliferative capacity of osteogenic stem cells are maintained during aging and in patients with osteoporosis. J Bone Miner Res. 2001;16(6):1120-1129.

113. Ipadpanah R, Trygg C, Kriedt C, Bunnell B. Biological comparison of mesenchymal stem cells derived from bone marrow and adipose tissue. Mol Ther. 2006;13:S134-S135.

114. Lindner U, Kramer J, Rohwedel J, Schlenke P. Mesenchymal stem or stromal cells: toward a better understanding of their biology? Transfus Med Hemoth. 2010;37(2):75-83.

115. Phinney DG. Functional heterogeneity of mesenchymal stem cells: Implications for cell therapy. J Cell Biochem. 2012;113(9):2806-2812.
116. Bianchi G, Banfi A, Mastrogiacomo M, et al. Ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2. Exp Cell Res. 2003;287(1):98-105.

117. Sotiropoulou PA, Perez SA, Salagianni M, Baxevanis CN, Papamichail M. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells. 2006;24(4):462-471.

118. Dhanasekaran M, Indumathi S, Lissa RP, Harikrishnan R, Rajkumar JS, Sudarsanam D. A comprehensive study on optimization of proliferation and differentiation potency of bone marrow derived mesenchymal stem cells under prolonged culture condition. Cytotechnology. 2013;65(2):187-197.

119. Aslan H, Zilberman Y, Kandel L, et al. Osteogenic differentiation of noncultured immunocompetent bone marrow-derived CD105+ cells. Stem Cells. 2006;24(7):1728-1737.

120. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.

121. Liebergall M, Schroeder J, Mosheiff R, et al. Stem cell-based therapy for delayed fracture union: a randomized and prospective preliminary study. Mol Ther. 2013;21(8):1631-1638.

122. O’Driscoll SW, Fitzsimmons JS. The role of periosteum in cartilage repair. Clin Orthop Relat Res. 2001;391:228-237.

123. Alsalameh S, Amin R, Gembka T, Lotz M. Identification of mesenchymal progenitor cells in normal and osteoarthritic human articular cartilage. Arthritis Rheumat. 2004;50(5):1522-1532.

124. Hiraoka K, Grogan S, Olee T, Lotz M. Mesenchymal progenitor cells in adult human articular cartilage. Biorheology. 2006;43(3-4):447-454.

125. de Mos M, Koevoet WJ, Jahr H, et al. Intrinsic differentiation potential of adolescent human tendon tissue: an in-vitro cell differentiation study. BMC Musculoskelet Dis. 2007;8:16.

126. Shen HC, Peng HR, Usas A, et al. Ex vivo gene therapy-induced endochondral bone formation: comparison of muscle-derived stem cells and different subpopulations of primary muscle-derived cells. Bone. 2004;34(6):982-992.

127. Wright VJ, Peng HR, Usas A, et al. BMP4-expressing muscle-derived stem cells differentiate into osteogenic lineage and improve bone healing in immunocompetent mice. Mol Ther. 2002;6(2):169-178.

128. Peng HR, Huard J. Muscle-derived stem cells for musculoskeletal tissue regeneration and repair. Transpl Immunol. 2004;12(3-4):311-319.

129. Kuhl T, Mezger M, Hauser I, Handgretinger R, Bruckner-Tuderman L, Nystrom A. High local concentrations of intradermal MSCs restore skin integrity and facilitate wound healing in dystrophic epidermolysis bullosa. Mol Ther. 2015;23(8):1368-1379.

130. Nakamura S, Yamada Y, Katagiri W, Sugito T, Ito K, Ueda M. Stem cell proliferation pathways comparison between human exfoliated deciduous teeth and dental pulp stem cells by gene expression profile from promising dental pulp. J Endodont. 2009;35(11):1536-1542.

131. Huang GTJ, Gronthos S, Shi S. Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine. J Dent Res. 2009;88(9):792-806.

132. Shi S, Bartold PM, Miura M, Seo BM, Robey PG, Gronthos S. The efficacy of mesenchymal stem cells to regenerate and repair dental structures. Orthod Craniofac Res. 2005;8(3):191-199.

133. Lanzoni G, Alviano F, Marchionni C, et al. Isolation of stem populations with trophic and immunoregulatory functions from human intestinal tissues: potential for cell therapy in inflammatory bowel disease. Cytotherapy. 2009;11(8):1020-1031.

134. Wang YN, Yu XP, Chen EM, Li LN. Liver-derived human mesenchymal stem cells: a novel therapeutic source for liver diseases. Stem Cell Res Ther. 2016;7:1-8.

135. Rotter N, Oder J, Lindner U, et al. Isolation and characterization of stem cells from different human salivary glands. Tissue Eng Part A. 2008;14(5):750-751.

136. Rotter N, Oder J, Schlenke P, et al. Isolation and characterization of adult stem cells from human salivary glands. Stem Cells Dev. 2008;17(3):509-518.

137. Mohshavirimia A, Chen C, Xu XT, et al. Bone regeneration potential of stem cells derived from periodontal ligament or gingival tissue sources encapsulated in RGD-modified alginate scaffold. Tissue Eng Part A. 2014;20(3-4):611-621.

138. Menicanin D, Mrozik KM, Wada N, et al. Periodontal-ligament-derived stem cells exhibit the capacity for long-term survival, self-renewal, and regeneration of multiple tissue types in vivo. Stem Cells Dev. 2014;23(9):1001-1011.

139. Zheng Y, Liu Y, Zhang CM, et al. Stem cells from deciduous tooth repair mandibular defect in swine. J Dent Res. 2009;88(3):249-254.

140. Kim SH, Kim KH, Seo BM, et al. Alveolar bone regeneration by transplantation of periodontal ligament stem cells and bone marrow stem cells in a canine peri-implant defect model: A pilot Study. J Periodontol. 2009;80(11):1815-1823.

141. d’Aquino R, De Rosa A, Lanza V, et al. Human mandible bone defect repair by the grafting of dental pulp stem/progenitor cells and collagen sponge biocomposites. Eur Cell Mater. 2009;18:75-83.

142. Giuliani A, Manescu A, Langer M, et al. Three years after transplants in human mandibles, histological and in-line holography revealed that stem cells regenerated a compact rather than a spongy bone: Biological and clinical implications. Stem Cells Trans Med. 2013;2(4):316-324.

143. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7(2):211-228.

144. Gronthos S, Franklin DM, Leddy HA, Robey PG, Storms RW, Gimble JM. Surface protein characterization of human adipose tissue-derived stromal cells. J Cell Physiol. 2001;189(1):54-63.

145. Rodriguez AM, Amri EZ, Ailhaud G, Dani C. The therapeutic potential of adipose-derived mesenchymal stem cells. Biochimie. 2005;87(1):125-128.

146. Lindroos B, Babilas P, Chasse L, et al. Serum-free, xeno-free culture media maintain the proliferation rate and multipotentiality of adipose stem cells in vitro. Cytotherapy. 2009;11(7):947-957.

147. Schreml S, Babilas P, Fruth S, et al. Harvesting human adipose tissue-derived adult stem cells: resection versus liposuction. Cytotherapy. 2009;11(7):947-957.

148. Hong SJ, Traktuev DO, March KL. Therapeutic potential of adipose-derived stem cells in vascular growth and tissue repair. Curr Opin Organ Tran. 2010;15(1):86-91.
187. Wagner W, Wein F, Seckinger A, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol. 2005;33(11):1402-1416.

188. Ishii M, Koike C, Igarashi A, et al. Molecular markers distinguish bone marrow mesenchymal stem cells from fibroblasts. Biochem Biophys Res Commun. 2005;332(1):297-303.

189. Sordi V, Malosio ML, Marchesi F, et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood. 2005;106(2):419-427.

190. Huss R. Isolation of primary and immortalized CD34(-) hematopoietic and mesenchymal stem cells from various sources. Stem Cells. 2000;18(1):1-9.

191. Simmons PJ, Torokstorb B. Identification of stromal cell precursors in human bone-marrow by a novel monoclonal antibody, Stro-1. Blood. 1991;78(1):55-62.

192. Planat-Benard V, Silvestre JS, Cousin B, et al. Plasticity of mesenchymal stem cells expresses a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood. 2005;106(2):419-427.

193. Scherberich A, Galli R, Jaquieri C, Farhadi J, Martin I. Three-dimensional perfusion culture of human adipose tissue-derived endothelial and osteoblastic progenitors generates osteogenic constructs with intrinsic vascularization capacity. Stem Cells. 2007;25(7):1823-1829.

194. Boquest AC, Shahdadfar A, Brinchmann JE, Collas P. Isolation of stromal stem cells from human adipose tissue - physiological and therapeutic perspectives. Circulation. 2004;109(5):656-663.

195. Varma MJO, Breuls RGM, Schouten TE, et al. Phenotypical and functional characterization of freshly isolated adipose tissue-derived stem cells. Stem Cells Dev. 2007;16(1):91-104.

196. Yoshimura K, Shigeura T, Matsumoto D, et al. Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates. J Cell Physiol. 2006;208(1):64-76.

197. Al-Nbaheen M, Vishnubalaji R, Ali D, et al. Human stromal (mesenchymal) stem cells from bone marrow, adipose tissue and skin exhibit differences in molecular phenotype and differentiation potential. Stem Cell Rev Rep. 2013;9(1):32-43.

198. Mitchell JB, McIntosh K, Zvonic S, et al. Immunophenotypic and stromal-associated and stem cell-associated markers. Stem Cells. 2006;24(2):376-385.

199. Lin CS, Ning HX, Lin GT, Lue TF. Is CD34 truly a negative marker for mesenchymal stromal cells? Cytotherapy. 2012;14(10):1159-1163.

200. Scherberich A, Di Maggio ND, McNagny KM. A familiar stranger: CD34 expression and putative functions in SVF cells of adipose tissue. World J Stem Cells. 2013;5(1):1-8.

201. Alfaro LAS, Dick SA, Siegel AL, et al. CD34 Promotes satellite cell motility and entry into proliferation to facilitate efficient skeletal muscle regeneration. Stem Cells. 2011;29(12):2030-2041.

202. Blanpain C, Lowry WE, Geoghagan A, Polak L, Fuchs E. Self-renewal, multipotency, and the existence of two cell populations within an epithelial stem cell niche. Cell. 2004;118(5):635-648.

203. Trempus CS, Morris RJ, Ehinger M, et al. CD34 expression by hair follicle stem cells is required for skin tumor development in mice. Cancer Res. 2007;67(9):4173-4181.

204. Trempus CS, Dang H, Humble MM, et al. Comprehensive microarray transcriptome profiling of CD34-enriched mouse keratinocyte stem cells. J Invest Dermatol. 2007;127(12):2904-2907.

205. Quirici N, Soligo D, Bossolasco P, Servida F, Lumini C, Delliliers GL. Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Hematol. 2002;30(7):783-791.

206. Kucí S, Kucí Z, Kreyenberg H, et al. CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica. 2010;95(4):651-659.

207. Halfon S, Abramov N, Grinblat B, Ginis I. Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passing. Stem Cells Dev. 2011;20(1):53-66.

208. Lecourt S, Marolleau JP, Fromigne O, et al. Characterization of distinct mesenchymal-like cell populations from human skeletal muscle in situ and in vitro. Exp Cell Res. 2010;316(15):2513-2526.

209. West-Mays JA, Dwivedi DJ. The keratocyte: corneal stromal cell with variable repair phenotypes. Int J Biochem Cell Biol. 2006;38(10):1625-1631.

210. Branch MJ, Hashmani K, Dhillon P, Jones DRE, Dua HS, Hopkinson A. Mesenchymal stem cells in the human corneal limbal stroma. Invest Ophth Vis Sci. 2012;53(9):5109-5116.

211. Hashmani K, Branch MJ, Sidney LE, et al. Characterization of corneal stromal stem cells with the potential for epithelial transdifferentiation. Stem Cell Res Ther. 2013;4:1-13.

212. Ning HX, Lin GT, Lue T, Lin CS. Mesenchymal stem cell marker Stro-1 is a 75kd endothelial antigen. Biochem Biophys Res Commun. 2011;413(2):353-357.

213. Sidney LE, Branch MJ, Dunphy SE, Dua HS, Hopkinson A. Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells. 2014;32(6):1380-1389.

214. Tintut Y, Alfonzo Z, Saini T, et al. Multilineage potential of cells from the artery wall. Circulation. 2003;108(20):2505-2510.

215. Lin GT, Liu G, Banie L, et al. Tissue distribution of mesenchymal stem cell marker Stro-1. Stem Cells Dev. 2011;20(10):1747-1752.

216. Tang W, Zeve D, Suh JM, et al. White fat progenitor cells reside in the adipose vasculature. Science. 2008;322(5901):583-586.

217. Holmes C, Stanford WL. Concise review: stem cell antigen-1: expression, function, and enigma. Stem Cells. 2007;25(6):1339-1347.

218. Crisan M, Yap S, Casteilla L, et al. Perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3(3):301-313.

219. Caplan AI. All MSCs are pericytes? Cell Stem Cell. 2008;3(3):229-230.

220. Hoshino A, Chiba H, Nagai K, Ishii G, Ochiai A. Human vascular adventitial fibroblasts contain mesenchymal stem/progenitor cells. Biochem Biophys Res Commun. 2008;368(2):305-310.

221. Corselli M, Chen CW, Crisan M, Lazzari L, Peault B. Perivascular ancestors of adult multipotent stem cells. Arterioscler Thromb Vasc Biol. 2010;30(6):1104-1109.

222. Corselli M, Chen CW, Sun B, Yap S, Rubin JP, Peault B. The tunica adventitia of human arteries and veins as a source of mesenchymal stem cells. Stem Cells Dev. 2012;21(8):1299-1308.
223. Crisan M, Corselli M, Chen WCW, Peault B. Perivascular cells for regenerative medicine. J Cell Mol Med. 2012;16(12):2851-2860.

224. Corselli M, Crisan M, Murray IR, et al. Identification of perivascular mesenchymal stromal/stem cells by flow cytometry. Cytom Part A. 2013;83A(8):714-720.

225. James AW, Zara JN, Corselli M, et al. An abundant perivascular source of stem cells for bone regeneration. Jove. 2012(63):e2952.

226. James AW, Zara JN, Corselli M, et al. Use of human perivascular stem cells for bone regeneration. Jove. 2012(63):e2952.

227. Chung CG, James AW, Asatrian G, et al. Human perivascular stem cell-based bone graft substitute induces rat spinal fusion. Stem Cells Trans Med. 2014;3(10):1231-1241.

228. Chavez-Munoz C, Nguyen KT, Xu W, Hong SJ, Mustoe TA, Hofer HR, Tuan RS. Secreted trophic factors of mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair - current views. PLoS One. 2013;8(12).

229. Phinney DG, Prockop DJ. Concise review: mesenchymal and engraftment, cell-targeting strategies, and immune modulation. Stem Cells Trans Med. 2012;1(9):673-684.

230. Kean TJ, Lin P, Caplan AI, Dennis JE. MSCs: delivery routes and engraftment, cell-targeting strategies, and immune modulation. Stem Cells Int. 2013;Article ID 732742.

231. Guimaraes-Camboa N, Cattaneo P, Sun Y, et al. Pericytes of multiple organs do not behave as mesenchymal stem cells in vivo. Cell Stem Cell. 2017;20(3):345-359 e345.

232. Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med. 2013;45:e54.

233. Rohban R, Pieber TR. Mesenchymal stem and progenitor cells in regeneration: tissue specificity and regenerative potential. Stem Cells Int. 2017;2017:5173732.

234. Caplan AI. New MSC: MSCs as pericytes are sentinels and gatekeepers. J Orthop Res. 2017;35(6):1159-1159.

235. Hofer HR, Tuan RS. Secreted trophic factors of mesenchymal stem cells support neurovascular and musculoskeletal therapies. Stem Cell Res Ther. 2016;7:131.

236. Kocan B, Maziarz A, Tabarkiewicz J, Ochiya T, Banas-Zabczyk A. Trophic activity and phenotype of adipose tissue-derived stem cells as a background of their immunosuppressive potential. Stem Cells Int. 2017;2017:1653254.

237. Liu H, Li D, Zhang Y, Li M. Inflammation, mesenchymal stem cells and bone regeneration. Histochem Cell Biol. 2018;149(4):393-404.

238. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(4):1815-1822.

239. Bai LH, Lennon DP, Eaton V, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia. 2009;57(11):1192-1203.

240. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15.

241. Caplan AI. What’s in a name? Tissue Eng Part A. 2010;16(8):2415-2417.

242. Muschler GF, Nitto H, Boehm CA, Easley KA. Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. J Orthop Res. 2001;19(1):117-125.

243. Stolzing A, Jones E, McGonagle D, Scott A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev. 2008;129(3):163-173.

244. Bruna F, Contador D, Conget P, Erranz B, Sossa CL, Arango-Rodriguez ML. Regenerative potential of mesenchymal stromal cells: age-related changes. Stem Cells Int. 2016;2016:1461648.

245. Schimke MM, Marozin S, Lepperder G. Patient-specific age: the other side of the coin in advanced mesenchymal stem cell therapy. Front Physiol. 2015;6:362.

246. Faella W, Atoui R. Immunotolerant properties of mesenchymal stem cells: updated review. Stem Cells Int. 2016;2016:1859567.

247. Siegel G, Schafer R, Dazzi F. The immunosuppressive properties of mesenchymal stem cells. Transplantation. 2009;87(9):S45-S49.

248. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003;31(10):890-896.

249. Morandi F, Raffaghello L, Bianchi G, et al. Immunogenicity of human mesenchymal stem cells in HLA-class i-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells. 2008;26(5):1275-1287.

250. Li XY, Ding J, Zheng ZH, Li XY, Zhu Z, Zhu P. Long-term culture in vitro impairs the immunosuppressive activity of mesenchymal stem cells on T cells. Mol Med Rep. 2012;6(5):1183-1189.

251. Toma C, Wagner WR, Bowry S, Schwartz A, Villanueva F. Fate of culture-expanded mesenchymal stem cells in the microvasculature in vivo observations of cell kinetics. Cire Res. 2009;104(3):398-U204.

252. Lee RH, Pullin AA, Seo MJ, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5(1):54-63.

253. Kidd S, Spaeth E, Dembinski JL, et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells. 2009;27(10):2614-2623.

254. von Bahr L, Batsis I, Moll G, et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells. 2012;30(7):1575-1578.

255. Eliopoulos N, Stagg J, Lejeune L, Pommye S, Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class i- and class II-mismatched recipient mice. Blood. 2005;106(13):4057-4065.

256. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transcendocardial injection in patients with ischemic cardiomyopathy. The POSEIDON randomized trial. JAMA. 2012;308(22):2369-2379.

257. Richardson C, Robins E, Raffagello L, Bianchi G, et al. Immunogenicity of mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells. 2008;26(5):1275-1287.

258. Lee RH, Pullin AA, Seo MJ, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5(1):54-63.

259. Kidd S, Spaeth E, Dembinski JL, et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells. 2009;27(10):2614-2623.

260. von Bahr L, Batsis I, Moll G, et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells. 2012;30(7):1575-1578.

261. Elijopoulos N, Stagg J, Lejeune L, Pommye S, Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood. 2005;106(13):4057-4065.
259. Berglund AK, Fortier LA, Antczak DF, Schnabel LV. Immuno-privileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells. *Stem Cell Res Ther.* 2017;8:1-7.

260. Rubio D, Garcia-Castro J, Martin MC, et al. Spontaneous human adult stem cell transformation. *Cancer Res.* 2005;65(8):3035-3039.

261. Wang Y, Huso DL, Harrington J, et al. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. *Cytotherapy.* 2005;7(6):509-519.

262. Mori S, Chang JT, Andrechek ER, et al. Anchorage-independent cell growth signature identifies tumors with metastatic potential. *Oncogene.* 2009;28(31):2796-2805.

263. Rosland GV, Svendsen A, Torsvik A, et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. *Cancer Res.* 2009;69(13):5331-5339.

264. Zhou YF, Bosch-Marce M, Okuyama H, et al. Spontaneous transformation of cultured mouse bone marrow-derived stromal cells. *Cancer Res.* 2006;66(22):10849-10854.

265. Ren ZH, Wang JY, Zhu WW, et al. Spontaneous transformation of adult mesenchymal stem cells from cynomolagus macaques *in vitro.* *Exp Cell Res.* 2011;317(20):2950-2957.

266. Garcia S, Bernad A, Osborn MJ, et al. Sarcoma derived from cultured mesenchymal stem cells. *Stem Cells.* 2007;25(2):371-379.

267. Garcia S, Bernad A, Martin MC, et al. Pitfalls in spontaneous *in vitro* transformation of human mesenchymal stem cells. *Exp Cell Res.* 2010;316(9):1648-1650.

268. Torsvik A, Rosland GV, Svendsen A, et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research Field on track (Correction letter for Cancer Res. 2009 Jul 1, 69(13), 5331–9). *Cancer Res.* 2010;70(15):6393-6396.

269. Torsvik A, Rosland GV, Bjerkvig R. Comment to: “Spontaneous transformation of adult mesenchymal stem cells from cynomolagus macaques *in vitro*” by Z. Ren et al. *Exp. Cell Res.* 2012;318(5):441-443.

270. Podolanczuk A, Psaila B, Lyden D. Role of bone microenvironment/metastatic niche in cancer progression. *Bone and cancer. Topics in bone biology.* London: Springer; 2010:59-101.

271. Park C, Lee JY, Yoon YS. Role of Bone marrow-derived lymphatic endothelial progenitor cells for lymphatic neovascularization. *Trends Cardiovas Med.* 2011;21(5):135-140.

272. Omelchenko DO, Rzhaninova AA, Gol’dshein DV. Comparative transcriptome pairwise analysis of spontaneously transformed multipotent stromal cells from human adipose tissue. *Russ J Genet.* 2014;50(1):96-104.

273. Pan Q, Foursachen SM, de Ruiter PE, et al. Detection of spontaneous tumorigenic transformation during culture expansion of human mesenchymal stromal cells. *Exp Biol Med (Maywood).* 2014;239(1):105-115.

274. Marrazzo P, Paduano F, Palmieri F, Marrelli M, Tatullo M. Highly efficient *in vitro* reparative behaviour of dental pulp stem cells cultured with standardised platelet lysate supplementation. *Stem Cells Int.* 2016;2016:7230987.

275. Tatullo M, Codispoti B, Paduano F, Nuzzolese M, Makeeva I. Strategic tools in regenerative and translational dentistry. *Int J Mol Sci.* 2019;20(8):1879.

276. Lye KL, Nordin N, Vidyadaran S, Thilakavathy K. Mesenchymal stem cells: from stem cells to sarcomas. *Cell Biol Int.* 2016;40(6):610-618.

277. Djouad F, Noel D, Noel D, et al. Immunosuppressive effect of mesenchymal stem cells in collagen-induced arthritis. *Arthritis Rheumat.* 2003;48(9):S550-S550.

278. Djouad F, Pience P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. *Blood.* 2003;102(10):3837-3844.

279. Karnoub AE, Weinberg RA. Chemokine networks and breast cancer metastasis. *Breast Dis.* 2006;26:75-85.

280. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. *Nature.* 2007;449(7162):557-U554.

281. Cuillo BG, Karnoub AE. Mesenchymal stem cells in tumor development: emerging roles and concepts. *Cell Adhesion Migr.* 2012;6(3):220-230.

282. Kim JH, Lee YT, Hong JM, Hwang YI. Suppression of in vitro murine T cell proliferation by human adipose tissue-derived mesenchymal stem cells is dependent mainly on cyclooxygenase-2 expression. *Anatomy Cell Biol.* 2013;46(4):262-271.

283. Mohammadzadeh A, Pourfathollah AA, Shahrokhi S, Hashemi SM, Moradi SLA, Soleimani M. Immunomodulatory effects of adipose-derived mesenchymal stem cells on the gene expression of major transcription factors of T cell subsets. *Int Immunopharmacol.* 2014;20(2):316-321.

284. Holt DDC, Wood JA, Granick JL, Walker NJ, Clark KC, Borjesson DL. Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue Source. *Stem Cells Dev.* 2014;23(11):1258-1265.

285. Akimoto K, Kimura K, Nagano M, et al. Umbilical cord blood-derived mesenchymal stem cells inhibit, but adipose tissue-derived mesenchymal stem cells promote, glioblastoma multiforme proliferation. *Stem Cells Dev.* 2013;22(9):1370-1386.

286. Ren GW, Zhao X, Wang Y, et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNF alpha. *Cell Stem Cell.* 2012;11(6):812-824.

287. Weiss ML, Medicetty S, Bledsoe AR, et al. Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson’s disease. *Stem Cells.* 2006;24(3):781-792.

288. Conconi MT, Burra P, Di Liddo R, et al. CD105 (+) cells from Wharton’s jelly show *in vitro* and *in vivo* myogenic differentiative potential. *Int J Mol Med.* 2006;18(6):1089-1096.

289. Lu LL, Liu YJ, Yang SG, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. *Haematologica.* 2006;91(8):1017-1026.

290. Zhou C, Yang B, Tian Y, et al. Immunomodulatory effect of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells on lymphocytes. *Cell Immunol.* 2011;272(1):33-38.

291. He H, Nagamura-Inoue T, Takahashi A, et al. Immunomodulatory properties of Wharton’s jelly-derived mesenchymal stromal cells *in vitro.* *Int J Hematol.* 2015;102:368-378.

292. Davies JE, Walker JT, Keating A. Concise review: Wharton’s jelly: the rich, but enigmatic, source of mesenchymal stromal cells. *Stem Cells Trans Med.* 2017;6(7):1620-1630.
293. Jaiswal RK, Jaiswal N, Bruder SP, Mbalaviele G, Marshak DR, Pittenger MF. Adult human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by mitogen-activated protein kinase. J Biol Chem. 2000;275(13):9645-9652.

294. Li CS, Zheng Z, Su XX, et al. Activation of the extracellular signal-regulated kinase signaling is critical for human umbilical cord mesenchymal stem cell osteogenic differentiation. Biomed Res Int. 2016;2016:2764372.

295. Can A, Karaheysingolu S. Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells. Stem Cells. 2007;25(11):2886-2895.

296. Baksh D, Yao R, Tuan RS. Comparison of proliferative and multilineage differentiation potential of human umbilical stem cells derived from umbilical cord and bone marrow. Stem Cells. 2007;25(6):1384-1392.

297. Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE. Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells. 2005;23(2):220-229.

298. Hjortholm N, Jaddini E, Halaburda K, Snarski E. Strategies of pain reduction during the bone marrow biopsy. Ann Hematol. 2013;92(2):145-149.

299. Bosch J, Houben AP, Radke TF, et al. Distinct differentiation potential of “MSC” derived from cord blood and umbilical cord: are cord-derived cells true mesenchymal stromal cells? Stem Cells Dev. 2012;21(11):1977-1988.

300. Subramanian A, Shu-Uin G, Kae-Siang N, et al. Human umbilical cord Wharton’s jelly mesenchymal stem cells do not transform to tumor-associated fibroblasts in the presence of breast and ovarian cancer cells unlike bone marrow mesenchymal stem cells. J Cell Biochem. 2012;113(6):1886-1895.

301. Klontzas ME, Kenanidis EI, Heliotis M, Tsiridis E, Mantalaris A. Bone and cartilage regeneration with the use of umbilical cord mesenchymal stem cells. Expert Opin Biol Ther. 2015;15:1541-1552.

302. Nanae A, Kohnen G, Milovanov AP, Domogatsky SP, Kaufman P. Stromal differentiation and architecture of the human umbilical cord. Placenta. 1997;18(1):53-64.

303. Schugar RC, Chirieleison SM, Wescoe KE, et al. High harvest yield, high expansion, and phenotype stability of CD146 mesenchymal stromal cells from whole primitive human umbilical cord tissue. J Biomed Biotechnol. 2009;2009:789526.

304. Whittle WL, Gibb W, Challis JRG. The characterization of human amnion epithelial and mesenchymal cells: the cellular expression, activity and glucocorticoid regulation of prostaglandin output. Placenta. 2000;21(4):394-401.

305. Insuasti CL, Blanquer M, Bleda P, et al. The amniotic membrane as a source of stem cells. Histol Histopathol. 2010;25(1):91-98.

306. Parolini O, Alviano F, Bagnara GP, et al. Concise review: isolation and characterization of cells from human term placenta: outcome of the first international workshop on placenta derived stem cells. Stem Cells. 2008;26(2):300-311.

307. Jeschke MG, Gauglitz GG, Phan TT, Herndon DN, Kita K. Umbilical cord lining membrane and Wharton’s jelly-derived mesenchymal stem cells: the similarities and differences. Open Tissue Eng Regen Med J. 2011;11(4):21-27.

308. Pu L, Meng MY, Wu J, et al. Compared to the amniotic membrane, Wharton’s jelly may be a more suitable source of mesenchymal stem cells for cardiovascular tissue engineering and clinical regeneration. Stem Cell Res Ther. 2017;8.

309. Subramanian A, Fong CY, Biswas A, Bongso A. Comparative characterization of cells from the various compartments of the human umbilical cord shows that the Wharton’s jelly compartment provides the best source of clinically utilizable mesenchymal stem cells. PLoS One. 2015;10(6):e0127992.

310. Mennc N, Wright K, Bhattacharjee A, Balain B, Richardson J, Roberts S. Isolation and characterisation of mesenchymal stem cells from different regions of the human umbilical cord. Biomed Res Int. 2013;2013:916136.

311. Wang P, Liu X, Zhao L, et al. Bone tissue engineering via human induced pluripotent, umbilical cord and bone marrow mesenchymal stem cells in rat cranium. Acta Biomater. 2015;18:236-248.

312. Salehinejad P, Alitheen NB, Ali AM, et al. Comparison of differerent methods for the isolation of mesenchymal stem cells from human umbilical cord Wharton’s jelly. In Vitro Cell Develop Biol Anim. 2012;48(2):75-83.

313. Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan CV. Wharton’s jelly-derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci. 2013;14(6):11692-11712.

314. Anzalone R, Lo Iacono M, Corrao S, et al. New emerging potentials for human Wharton’s jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity. Stem Cells Dev. 2010;19(4):423-438.

315. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol. 2000;109(1):235-242.

316. Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood. 2004;103(5):1669-1675.

317. Broxmeyer HE, Douglas GW, Hangoc G, et al. Human umbilical-cord blood as a potential source of transplantable hematopoietic stem progenitor Cells. PNAS. 1989;86(10):3828-3832.

318. Liu GP, Li YL, Sun J, et al. In vitro and in vivo evaluation of osteogenesis of human umbilical cord blood-derived mesenchymal stem cells on partially demineralized bone matrix. Tissue Eng Part A. 2010;16(3):971-982.

319. Marmotti A, Mattia S, Castoldi F, et al. Allogeneic umbilical cord-erived mesenchymal stem cells as a potential source for cartilage and bone regeneration: an in vitro study. Stem Cells Int. 2017;Article ID 1732094.

320. Secco M, Zucconi E, Vieira NM, et al. Multipotent stem cells from umbilical cord: cord is richer than blood! Stem Cells. 2008;26(1):146-150.

321. Zeddou M, Briquet A, Relic B, et al. The umbilical cord matrix is a better source of mesenchymal stem cells (MSC) than the umbilical cord blood. Cell Biol Int. 2010;34(7):693-701.

322. Secunda R, Vennila R, Mohanashankar AM, Rajasundari M, Jeswathan S, Surendran R. Isolation, expansion and characterization of mesenchymal stem cells from human bone marrow, adipose tissue, umbilical cord blood and matrix: a comparative study. Cytotechnology. 2015;67(5):793-807.

323. Renda MC, Fecarotta E, Schillaci G, et al. Mesenchymal fetal stem cells (fMSC) from amniotic fluid (AF): expansion and phenotypic characterization. Blood. 2015;126(23):4758.
324. Moraghebi R, Kirkeby A, Chaves P, et al. Term amniotic fluid: an unexploited reserve of mesenchymal stromal cells for reprogramming and potential cell therapy applications. Stem Cell Res Ther. 2017;8:1-12.

325. Dziadosz M, Young BK, Basch RS. Human amniotic fluid: a source of stem cells for possible therapeutic use. Rep. Am J Obstet Gynecol. 2016;215(3):401.

326. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145-1147.

327. Prelle K, Zink N, Wolf E. Pluripotent stem cells - model of embryonic development, tool for gene targeting, and basis of cell therapy. Anat Histol Embryol. 2002;31(3):169-186.

328. Winkler J, Sotiriadou I, Chen S, Hescheler J, Sachinidis A. The potential of embryonic stem cells combined with -omics technologies as model systems for toxicology. Curr Med Chem. 2009;16(36):4814-4827.

329. Pouton CW, Haynes JM. Embryonic stem cells as a source of models for drug discovery. Nat Rev Drug Discov. 2007;6(8):605-616.

330. Liu WW, Deng YG, Liu Y, Gong WR, Deng WB. Stem cell models for drug discovery and toxicology studies. J Biochem Mol Toxic. 2013;27(1):17-27.

331. Avior Y, Sagi I, Benvenisty N. Pluripotent stem cells in disease modelling and drug discovery. Nat Rev Mol Cell Bio. 2016;17(3):170-182.

332. Arpornmaeklong P, Brown SE, Wang Z, Krebsbach PH. Phenotypic characterization, osteoblastic differentiation, and bone regeneration capacity of human embryonic stem cell-derived mesenchymal stem cells. Stem Cells Dev. 2009;18(7):955-968.

333. Kuhn LT, Liu Y, Boyd NL, et al. Developmental-like bone regeneration by human embryonic stem cell-derived mesenchymal cells. Tissue Eng Part A. 2014;20(1-2):365-377.

334. Buttery LD, Bourne S, Yynos JD, et al. Differentiation of osteoblasts and in vitro bone formation from murine embryonic stem cells. Tissue Eng. 2001;7(1):89-99.

335. Bielby RC, Bocaccini AR, Polak JM, Buttery LD. In vitro differentiation and in vivo mineralization of osteogenic cells derived from human embryonic stem cells. Tissue Eng. 2004;10(9-10):1518-1525.

336. Liu X, Wang P, Chen W, Weir MD, Bao C, Xu HH. Human embryonic stem cells and macroporous calcium phosphate construct for bone regeneration in cranial defects in rats. Acta Biomater. 2014;10(10):4484-4493.

337. Sugarmann J. Human stem cell ethics: beyond the embryo. Cell Stem Cell. 2008;2(6):529-533.

338. Sugarmann J, Siegel A. How to determine whether existing human embryonic stem cell lines can be used ethically. Cell Stem Cell. 2008;3(3):238-239.

339. Monitoring Stem Cell Research. Washington, DC: The President's Council on Bioethics; 2004.

340. Hyun I, Willkerson A, Johnston J. Embryology policy: revisit the 14-day rule. Nature. 2016;533(7602):169-171.

341. Lo B, Parham L. Ethical issues in stem cell research. Endocr Rev. 2009;30(3):204-213.

342. Zavazava N. Embryonic stem cells and potency to induce transplantation tolerance. Expert Opin Biol Ther. 2003;3(1):5-13.

343. Li L, Baroja ML, Majumdar A, et al. Human embryonic stem cells possess immune-privileged properties. Stem Cells. 2004;22(4):448-456.

344. Koch CA, Geraldes P, Platt JL. Immunosuppression by embryonic stem cells. Stem Cells. 2008;26(1):89-98.

345. Araki R, Uda M, Hoki Y, et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature. 2013;494(7435):100-104.

346. Swijnenburg RJ, Tanaka M, Vogel H, et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation. 2005;112(9):1166-1172.

347. Grinnemo KH, Kumagai-Braesch M, Mansson-Broberg A, et al. Human embryonic stem cells are immunogenic in allogeneic and xenogeneic settings. Reprod Biomed Online. 2006;13(5):712-724.

348. Draper JS, Smith K, Gokhale P, et al. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat Biotechnol. 2004;22(1):53-54.

349. Enver T, Soneji S, Joshi C, et al. Cellular differentiation hierarchies in normal and culture-adapted human embryonic stem cells. Hum Mol Genet. 2005;14(21):3129-3140.

350. Mitalipova MM, Rao RR, Hoyer DM, et al. Preserving the genetic integrity of human embryonic stem cells. Nat Biotechnol. 2005;23(1):19-20.

351. Peterson SE, Loring JF. Genomic instability in pluripotent stem cells: implications for clinical applications. J Biol Chem. 2014;289(8):4578-4584.

352. Narva E, Autio R, Rahkonen N, et al. High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nat Biotechnol. 2010;28(4):371-U103.

353. Amps K, Andrews PW, Anyfantis G, et al. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol. 2011;29(12):1132-U1113.

354. Li JY, Christophersen NS, Hall V, Soulet D, Brundin P. Critical issues of clinical human embryonic stem cell therapy for brain repair. Trends Neurosci. 2008;31(4):146-153.

355. Werbowetski-Ogilvie TE, Bosse M, Stewart M, et al. Characterization of human embryonic stem cells with features of neoplastic progression. Nat Biotechnol. 2009;27(1):91-97.

356. Lee AS, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity of embryonic stem cell lines derived from mouse induced pluripotent stem cells. Stem Cells. 2013;19(8):998-1004.

357. Takahashi K, Yamanaka S. Induction of pluripotent stem cells by adenoviral transduction. Science. 2007;318(5858):1917-1920.

358. Lowry WE, Richter L, Yachechko R, et al. Generation of human induced pluripotent stem cell lines derived from human somatic cells. Science. 2009;325(5943):1433-1436.

359. Vodyanik MA, Smyk-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2008;318(5858):1917-1920.

360. Liu J, Brzeszczynska J, Samuel K, et al. Efficient episomal adenoviral transduction of human embryonic stem cells. Nat Biotechnol. 2009;27(8):1802-1811.
362. Kao CL, Tai HK, Chou SH, et al. Resveratrol promotes osteogenic differentiation and protects against dexamethasone damage in murine induced pluripotent stem cells. *Stem Cells Dev.* 2010;19(2):247-258.

363. Li F, Bronson S, Niyibizi C. Derivation of murine induced pluripotent stem cells (iPS) and assessment of their differentiation toward osteogenic lineage. *J Cell Biochem.* 2010;109(4):643-652.

364. Yelousova G, Jun DH, King KB, et al. Osteoblasts derived from induced pluripotent stem cells: Form calcified structures in scaffolds both in vitro and in vivo. *Stem Cells.* 2011;29(2):206-216.

365. Ye JH, Xu YJ, Gao J, et al. Critical-size calvarial bone defects healing in a mouse model with silk scaffolds and SATB2-modified iPSCs. *Biomaterials.* 2011;32(22):5065-5076.

366. Li F, Niyibizi C. Cells derived from murine induced pluripotent stem cells (iPSC) by treatment with members of TGF-beta family give rise to osteoblasts differentiation and form bone in vivo. *BMC Cell Biol.* 2012;13:35.

367. Hayashi T, Misawa H, Nakahara H, et al. Transplantation of osteogenically differentiated mouse iPSCs for bone repair. *Cell Transplant.* 2012;21(2-3):591-600.

368. Villa-Diaz LG, Brown SE, Liu Y, et al. Derivation of mesenchymal stem cells from human induced pluripotent stem cells cultured on synthetic substrates. *Stem Cells.* 2012;30(6):1174-1181.

369. Nasu A, Ikeya M, Yamamoto T, et al. Genetically matched human iPSC cells reveal that propensity for cartilage and bone differentiation differs with clones, not cell Type of origin. *PLoS One.* 2013;8(1).

370. Liu J, Chen WC, Zhao ZH, Xu HHK. Reprogramming of mesenchymal stem cells derived from iPSCs seeded on biofunctionalized calcium phosphate scaffold for bone engineering. *Biomaterials.* 2013;34(32):7862-7872.

371. TheinHan WW, Liu J, Tang MH, Chen WC, Cheng LZ, Xu HHK. Induced pluripotent stem cell-derived mesenchymal stem cell seeding on biofunctionalized calcium phosphate cements. *Bone Res.* 2013;1:371-384.

372. Ardeshirylajimi A, Hosseinkhani S, Parivar K, Yaghmaie P, Soleimani M. Nanoﬁber-based polyethersulfone scaffold and efficient differentiation of human induced pluripotent stem cells into osteoblastic lineage. *Mol Biol Rep.* 2013;40(7):4287-4294.

373. Tang MH, Chen WC, Liu J, Weir MD, Cheng LZ, Xu HHK. Human induced pluripotent stem cell-derived mesenchymal stem cell seeding on calcium phosphate scaffold for bone regeneration. *Tissue Eng Part A.* 2014;20(7-8):1295-1305.

374. Ochiai-Shino H, Kato H, Sawada T, et al. A novel strategy for enrichment and isolation of osteoprogenitor cells from induced pluripotent stem cells based on surface marker combination. *PLoS One.* 2014;9(6):e99534.

375. Ko JY, Park S, Im GI. Osteogenesis from human induced pluripotent stem cells: an in vitro and in vivo comparison with mesenchymal stem cells. *Stem Cells Dev.* 2014;23(15):1786-1797.

376. Egusa H, Kayashima H, Miura J, et al. Comparative analysis of mouse-induced pluripotent stem cells and mesenchymal stem cells during osteogenic differentiation in vitro. *Stem Cells Dev.* 2014;23(18):2156-2169.

377. Liu J, Chen WC, Zhao ZH, Xu HHK. Effect of NELL1 gene overexpression in iPSC-MSCs seeded on calcium phosphate cement. *Acta Biomater.* 2014;10(12):5128-5138.

378. Ji J, Tong X, Huang X, Zhang J, Qin H, Hu Q. Patient-derived human induced pluripotent stem cells from gingival fibroblasts harvested from patients with osteoporosis in vivo and in vitro. *J Dent Res.* 2016;95(11):2156-2169.

379. Ardeshirylajimi A, Soleimani M. Enhanced growth and osteogenic differentiation of induced pluripotent stem cells by extremely low-frequency electromagnetic field. *Cell Mol Biol.* 2015;61(1):36-41.

380. Kato H, Ochiai-Shino H, Onodera S, Saito A, Shibahara T, Azuma T. Promoting effect of 1,25(OH)(2) vitamin D-3 in osteogenic differentiation from induced pluripotent stem cells to osteocyte-like cells. *Open Biol.* 2015;5(2).

381. Okawa H, Kayashima H, Sasaki JI, et al. Scaffold-free fabrication of osteoinductive cellular constructs using mouse gingiva-derived induced pluripotent stem cells. *Stem Cells Int.* 2016;2016:6240794.

382. Wang P, Song Y, Weir MD, et al. A self-setting iPSC-alginate-calcium phosphate paste for bone tissue engineering. *Dent Mater.* 2016;32(2):252-263.

383. Xie J, Peng C, Zhao QH, et al. Osteogenic differentiation and bone regeneration of iPSC-MSCs supported by a biomimetic nanofibrous scaffold. *Acta Biomater.* 2016;29:365-379.

384. Hynes K, Menicanin D, Han J, et al. Mesenchymal stem cells from iPSCs facilitate periodontal regeneration. *J Dent Res.* 2013;92(9):833-839.

385. Tsuji O, Miura K, Okada Y, et al. Therapeutic potential of human-induced pluripotent stem cell-derived mesenchymal cells and bone marrow-derived mesenchymal stromal cells from the same donor. *Stem Cells Dev.* 2014;23(14):1594-1610.

386. de Peppo GM, Marcos-Campos I, Kahler DJ, et al. Engineering bone tissue substitutes from human induced pluripotent stem cells. *PNAS.* 2013;110(21):8680-8685.

387. Zou LJ, Luo YL, Chen MW, et al. A simple method for deriving functional MSCs and applied for osteogenesis in 3D scaffolds. *Sci Rep.* 2013;3.

388. Dogaki Y, Lee SY, Niikura T, et al. Efficient differentiation of osteoprogenitor cells from induced pluripotent stem cells for bone regeneration. *Int Orthop.* 2014;38(9):1779-1785.

389. Hynes K, Menicanin D, Mrozik K, Gronthos S, Bartold PM. Generation of functional mesenchymal stem cells from different induced pluripotent stem cell lines. *Stem Cells Dev.* 2014;23(10):1084-1096.

390. Kang R, Luo YL, Zou LJ, et al. Osteogenesis of human induced pluripotent stem cells derived mesenchymal stem cells on hydroxyapatite contained nanofibers. *RSC Adv.* 2014;4(11):5734-5739.

391. Hong SG, Winkler T, Wu CF, et al. Path to the clinic: Assessment of iPSC-based cell therapies in vivo in a nonhuman primate model. *Cell Rep.* 2014;7(4):1298-1309.

392. Ishiy FAA, Fanganiello RD, Griesi-Oliveira K, et al. Improvement of in vitro osteogenic potential through differentiation of induced pluripotent stem cells from human exfoliated dental tissue towards mesenchymal-like stem cells. *Stem Cells Int.* 2015;2015:249098.

393. Lepage SI, Nagy K, Sung HK, Kandel RA, Nagy A, Koch TG. Generation, characterization, and multilineage potency of...
mesenchymal-like progenitors derived from equine induced pluripotent stem cells. Stem Cells Dev. 2016;25(1):80-89.

395. Kang R, Zhou Y, Tan S, et al. Mesenchymal stem cells derived from human induced pluripotent stem cells retain adequate osteogenicity and chondrogenicity but less adipogenicity. Stem Cell Res Ther. 2015;6:144.

396. Lian QZ, Zhang YL, Zhang JQ, et al. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation. 2010;121(9):1113-U119.

397. Liu Y, Goldberg AJ, Dennis JE, Gronowicz GA, Kuhn LT. One-step derivation of mesenchymal stem cell (MSC)-like cells from human pluripotent stem cells on a fibrillar collagen coating. PLoS One. 2012;7(3):e33225.

398. Duan X, Tu Q, Zhang J, et al. Application of induced pluripotent stem (iPS) cells in periodontal tissue regeneration. J Cell Physiol. 2011;226(1):150-157.

399. Levi B, Hyun JS, Montoro DT, et al. In vivo directed differentiation of pluripotent stem cells for skeletal regeneration. PNAS. 2012;109(50):20379-20384.

400. Jia FJ, Wilson KD, Sun N, et al. A nonviral minicircle vector for virus-free induction of pluripotency and subsequent differentiation of human induced pluripotent stem cells. Stem Cell Rev Rep. 2011;7(3):771-775.

401. Malecki M. ‘Above all, do no harm’: safeguarding pluripotent stem cell therapy against iatrogenic tumorigenesis. Stem Cell Res Ther. 2014;5(3):73.

402. Adegani FJ, Soleimani M. Enhanced reconstruction of rat calvarial defects achieved by plasma-treated electrospun scaffolds and induced pluripotent stem cells. Cell Tissue Res. 2013;354(3):849-860.

403. Wang MK, Deng Y, Zhou P, et al. In vitro and directed osteogenic differentiation of human pluripotent stem cells generated without viral integration. Science. 2008;322(5903):949-951.

404. Chou BK, Mali P, Huang XS, et al. Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell. 2010;141(5):949-953.

405. Wang MK, Deng Y, Zhou P, et al. In vitro culture and directed osteogenic differentiation of human pluripotent stem cells on peptides-decorated two-dimensional microenvironment. ACS Appl Mater Interfaces. 2015;7(8):4560-4572.

406. Anguera MC, Sadreyev R, Zhang ZQ, et al. Molecular signatures of human induced pluripotent stem cells highlight sex differences and cancer genes. Cell Stem Cell. 2012;11(1):75-90.

407. Yu JY, Hu KJ, Smuga-Otto K, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science. 2009;324(5928):797-801.

408. Nagy K, Sung HK, Zhang PZ, et al. Induced pluripotent stem cell lines derived from equine fibroblasts. Stem Cell Rev Rep. 2011;7(3):693-702.

409. Yoshioka N, Gros E, Li HR, et al. Efficient generation of human iPSCs by a synthetic self-replicating RNA. Cell Stem Cell. 2013;13(2):246-254.
human cells with synthetic modified mRNA. *Cell Stem Cell*. 2010;7(5):618-630.

429. Miyoshi N, Ishii H, Nagano H, et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. *Cell Stem Cell*. 2011;8(6):635-638.

430. Kim D, Kim CH, Moon Ji, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. *Cell Stem Cell*. 2009;4(6):472-476.

431. Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. *Cell Stem Cell*. 2009;4(5):381-384.

432. Moriguchi H, Chung RT, Sato C. Tumorigenicity of human induced pluripotent stem cells depends on the balance of gene expression between p21 and p53. *Hepatology*. 2010;51(3):1088-1089.

433. Pei DQ. The magic continues for the iPS strategy. *Cell Res*. 2008;18(2):221-223.

434. Huangfu D, Osafune K, Maehr R, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. *Nat Biotechnol*. 2008;26(11):1269-1275.

435. Shi Y, Do JT, Desponts C, Hahn HS, Scholer HR, Ding S. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. *Cell Stem Cell*. 2008;2(6):525-528.

436. Shi Y, Desponts C, Do JT, Hahn HS, Scholer HR, Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. *Cell Stem Cell*. 2008;2(3):568-574.

437. Xu Y, Shi Y, Ding S. A chemical approach to stem-cell biology and regenerative medicine. *Nature*. 2008;453(7193):338-344.

438. Pei DQ. Regulation of pluripotency and reprogramming by transcription factors. *J Biol Chem*. 2009;284(6):3365-3369.

439. Ichida JK, Blanchard J, Lam K, et al. A small-molecule inhibitor of Tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. *Cell Stem Cell*. 2009;5(5):491-503.

440. Zhu SY, Li WL, Zhou HY, et al. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. *Cell Stem Cell*. 2010;7(6):651-655.

441. Chen JK, Liu J, Yang JQ, et al. BMPs functionally replace Klf4 and support efficient reprogramming of mouse fibroblasts by Oct4 alone. *Cell Res*. 2011;21(1):205-212.

442. Chen JK, Liu J, Chen Y, et al. Rational optimization of reprogramming culture conditions for the generation of induced pluripotent stem cells with ultra-high efficiency and fast kinetics. *Cell Res*. 2011;21(6):884-894.

443. Li YQ, Zhang QA, Yin XL, et al. Generation of iPSCs from mouse fibroblasts with a single gene, Oct4, and small molecules. *Cell Res*. 2011;21(2):196-204.

444. Hou PP, Li YQ, Zhang X, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. *Science*. 2013;343(6146):651-654.

445. Zhao Y, Zhao T, Guan JY, et al. A XEN-like state bridges somatic cells to pluripotency during chemical reprogramming. *Cell*. 2015;163(7):1678-1691.

446. Long Y, Wang M, Gu HF, Xie X. Bromodeoxyuridine promotes full-chemical induction of mouse pluripotent stem cells. *Cell Res*. 2015;25(10):1711-1714.

447. Cao ST, Yu SY, Li DW, et al. Chromatin accessibility dynamics during chemical induction of pluripotency. *Cell Stem Cell*. 2018;22(4):529-542.

448. Kikuchi K, Masuda T, Fujiwara N, et al. Craniofacial bone regeneration using iPS cell-derived neural crest like cells. *J Hard Tissue Biol*. 2018;27(1):1-10.

449. Ortuno-Costela MD, Garcia-Lopez M, Cerrada V, Gallardo ME. iPSCs: a powerful tool for skeletal muscle tissue engineering. *J Cell Mol Mol*. 2019;23(6):3784-3794.

450. Wu C, Hong SG, Winkler T, et al. Development of an inducible caspase-9 safety switch for pluripotent stem cell-based therapies. *Mol Ther Methods Clin Dev*. 2014;1:14053.

451. Kimura Y, Shofuda T, Higuchi Y, et al. Human genomic safe harbors and the suicide gene-based safeguard system for iPSC-based cell therapy. *Stem Cells Trans Med*. 2019;8(7):627-638.

452. Gurdon JB. The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. *J Embryol Exp Morphol*. 1962;10:622-640.

453. Gurdon JB. Adult frogs derived from the nuclei of single somatic cells. *Dev Biol*. 1962;4:256-273.

454. Gurdon JB, Uehlinger V. “Fertile” intestine nuclei. *Nature*. 1966;210(5042):1240-1241.

455. Laskey RA, Gurdon JB. Genetic content of adult somatic cells tested by nuclear transplantation from cultured cells. *Nature*. 1970;228(5278):1332-1334.

456. Wilmut I, Schniecke AE, McWhir J, Kind AJ, Campbell KH. Viable offspring derived from fetal and adult mammalian cells. *Nature*. 1997;385(6619):810-813.

457. Wakayama T, Perry AC, Zuccotti M, Johnson KR, Yanagimachi R. Full-term development of mice from enucleated oocytes injected with cumulus cell nuclei. *Nature*. 1998;394(6691):369-374.

458. Byrne JA, Pedersen DA, Clepper LL, et al. Producing primate embryonic stem cells by somatic cell nuclear transfer. *Nature*. 2007;450(7196):497-502.

459. Tada M, Takahama Y, Abe K, Nakatsuji N, Tada T. Nuclear reprogramming of somatic cells by in vitro hybridization with ES cells. *Curr Biol*. 2001;11(19):1553-1558.

460. Cowan CA, Atienza J, Melton DA, Eggan K. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. *Science*. 2005;309(5739):1369-1373.

461. Hansis C, Barreto G, Maltry N, Niehrs C. Nuclear reprogramming of human somatic cells by xenopus egg extract requires BRG1. *Curr Biol*. 2004;14(16):1475-1480.

462. Zhu XQ, Pan XH, Wang W, et al. Transient in vitro epigenetic reprogramming of skin fibroblasts into multipotent cells. *Bio materials*. 2010;31(10):2779-2787.

463. Taranger CK, Noer A, Sorensen AL, Hakelien AM, Boquest AC, Collas P. Induction of dedifferentiation, genomewide transcriptional programming, and epigenetic reprogramming by extracts of carcinoma and embryonic stem cells. *Mol Biol Cell*. 2005;16(12):5719-5735.

464. Moore KA, Lemischka IR. Stem cells and their niches. *Science*. 2006;311(5769):1880-1885.

465. Mauro A, Turriani M, Ioannoni A, et al. Isolation, characterization, and in vitro differentiation of ovine amniotic stem cells. *Vet Res Commun*. 2010;34(4):S25-S28.

466. Antonucci I, Stuppia L, Kaneko Y, et al. Amniotic fluid as a rich source of mesenchymal stromal cells for transplantation therapy. *Cell Transplant*. 2011;20(6):789-795.

467. Kalaszczynska I, Ferdyn K. Wharton’s jelly derived mesenchymal stem cells: future of regenerative medicine? Recent findings and clinical significance. *Biomed Res Int*. 2015;2015:430847.
Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. *Nat Med.* 2007;13(10):1219-1227.

Oldberg A, Antonsson P, Lindblom K, Heinegard D. A collagen-binding 59-kd protein (fibromodulin) is structurally related to the small interstitial proteoglycans PG-S1 and PG-S2 (decorin). *EMBO J.* 1989;8(9):2601-2604.

Iozzo RV, Goldoni S, Berendsen AD, Young MF. Small leucine-rich proteoglycans: the extracellular matrix: an overview. In: Mecham RP, ed. *Biology of Extracellular Matrix.* Berlin, Heidelberg: Springer; 2011:197-231.

Paracuellos P, Kalamajski S, Bonna A, Bihan D, Farndale RW, Hohenester E. Structural and functional analysis of two small leucine-rich repeat proteoglycans, fibromodulin and chondroadherin. *Matrix Biol.* 2017;63:106-116.

Viola M, Bartolini B, Sonaggere M, Giudici C, Tenni R, Tira ME. Fibromodulin interactions with type I and II collagens. *Connect Tissue Res.* 2007;48(3):141-148.

Hildebrand A, Romaris M, Rasmussen L, et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor β. *Biochem J.* 1994;302:527-534.

Kalamajski S, Bihan D, Bonna A, Rubin K, Farndale RW. Fibromodulin interacts with collagen cross-linking sites and activates lysyl oxidase. *J Biol Chem.* 2016;291(15):7951-7960.

Merline R, Schaefer RM, Schaefer L. The matricellular functions of small leucine-rich proteoglycans (SLRFs). *J Cell Commun Signal.* 2009;3(3-4):323-335.

Jian J, Zheng Z, Zhang K, et al. Fibromodulin promoted in vitro and in vivo angiogenesis. *Biochem Biophys Res Commun.* 2013;436:537-542.

Zheng Z, Jian J, Velasco O, et al. Fibromodulin enhances angiogenesis during cutaneous wound healing. *Plast Reconstr Surg Glob Open.* 2014;2(12):e275.

Adini I, Ghosh K, Adini A, et al. Melanocyte-secreted fibromodulin promotes an angiogenic microenvironment. *J Clin Invest.* 2014;124(1):425-436.

Zheng Z, Zhang X, Dang C, et al. Fibromodulin is essential for fetal-type scarless cutaneous wound healing. *Am J Pathol.* 2016;186(11):2824-2832.

Zheng Z, James AW, Li C, et al. Fibromodulin reduces scar formation in adult cutaneous wounds by eliciting a fetal-like phenotype. *Signal Transduct Target Ther.* 2017;2:17050.

Zheng Z, Jian J, Zhang X, et al. Reprogramming of human fibroblasts into multipotent cells with a single ECM proteoglycan, fibromodulin. *Biomaterials.* 2012;33(24):5821-5831.

Li CS, Yang P, Ting K, et al. Fibromodulin reprogrammed cells: a novel cell source for bone regeneration. *Biomaterials.* 2016;83:194-206.

Zheng Z, Li C, Ha P, et al. *CDKN2B* upregulation prevents teratoma formation in multipotent fibromodulin reprogrammed cells. *J Clin Invest.* 2019;129(8):3236-3251.

Yang P, Li C, Lee M, et al. Photopolymerizable hydrogel-encapsulated fibromodulin-reprogrammed cells for muscle regeneration. *Tissue Eng Part A.* 2020;26(19-20):1112-1122.

Fisch SC, Gimeno ML, Phan JD, et al. Pluripotent nontumorigenic multilineage differentiating stress enduring cells (Muse cells): a seven-year retrospective. *Stem Cell Res Ther.* 2017;8:227.

Wakao S, Kitada M, Kuroda Y, et al. Multilineage-differentiating stress-enduring (Muse) cells are a primary source of induced pluripotent stem cells in human fibroblasts. *PNAS.* 2011;108(24):9875-9880.

Wakao S, Kitada M, Dezawa M. The elite and stochastic model for iPS cell generation: multilineage-differentiating stress enduring (Muse) cells are readily reprogrammable into iPS cells. *Cytom Part A.* 2013;83A(1):18-26.

How to cite this article: Li C, Mills Z, Zheng Z. Novel cell sources for bone regeneration. *MedComm.* 2021;2:145–174. https://doi.org/10.1002/mco2.51